

Vaccines and Global Health: The Week in Review 31 August 2024 :: Issue 764 Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click <u>here</u> to donate and thank you in advance for your contribution.

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers
- :: Think Tanks

Editor's Note:

Vaccines and Global Health: The Week in Review resumes publication with this edition following annual leave for the Editor.

Milestones, Perspectives

::::::

Gaza - Polio vaccination

Polio vaccine campaign begins in Gaza a day before fighting is expected to pause

By ASSOCIATED PRESS, <u>JULIA FRANKEL</u>, SAMY MAGDY and <u>SAM METZ</u> Updated 5:02 PM EDT, August 31, 2024

JERUSALEM (AP) — A campaign to inoculate <u>children in Gaza against polio</u> and prevent the spread of the virus has begun, the Health Ministry said Saturday, as Palestinians in the Hamas-governed enclave and the occupied West Bank reeled from Israel's military offensives...

::::::

<u>Speakers in Security Council Urge Israel to Refrain from Military Action, Evacuation Orders in Gaza as UN, Aid Partners Prepare for Vaccine Campaign amid Polio Outbreak</u>

29 August 2024

SC/15805

As the United Nations and its humanitarian partners prepare for a vaccination campaign in Gaza to deal with the polio outbreak, speakers in the Security Council urged Israel to refrain from military operations and evacuation orders to ensure that those delivering and receiving services can do so safely.

The 10-month-old infant who died of polio in Gaza — after 25 years of a polio-free Palestine — was born during wartime and never vaccinated, reported Mike Ryan, Deputy Director-General and Executive Director of the Health Emergency Programme at the World Health Organization (WHO). "The current outbreak in Gaza is a stark reminder of how quickly infectious diseases can re-emerge in regions where health systems are compromised," he said, noting that many other maladies are spreading while the collective capacity to prevent, detect and respond to them continues to be hindered.

He therefore welcomed the commitment to "area-specific humanitarian pauses and suspension of evacuation orders" for the implementation of a two-round polio vaccination campaign, set to begin in Gaza on 1 September. During each round, the Palestinian Ministry of Health — in collaboration with WHO, the United Nations Children's Fund (UNICEF) and the United Nations Relief and Works Agency for Palestine Refugees in the Near East (UNRWA) — will provide two drops of a WHO-prequalified "nOPV2" vaccine to more than 640,000 children under 10 years of age.

The campaign will begin in central Gaza and then move south and finally north, with each area covered over three days. Noting that at least 90 per cent vaccination coverage during each round is needed to stop the outbreak and "prevent international spread of polio", he stressed that — due to factors such as insecurity, damaged infrastructure and constant displacement — "we know an additional day or two is very often needed to achieve sufficient coverage". "The safety of every single one of the over 2,180 vaccinators must be guaranteed," he underscored.

He also detailed the "much larger public health catastrophe" in which the polio outbreak is occurring. As of 25 August, only 44 per cent of primary health-care facilities are functional and attacks on health care continue to be reported. Evacuation orders are further disrupting health-care provision, endangering critical health infrastructure and hampering the delivery of essential supplies. Calling on

the international community to act now to secure humanitarian pauses, ensure the delivery of critical health supplies and support the rapid implementation of the polio vaccination campaign, he stressed: "The world cannot stand by as Gaza's health system crumbles under the weight of this conflict."

Also briefing the Council today was Joyce Msuya, Acting Under-Secretary-General for Humanitarian Affairs and Acting Emergency Relief Coordinator, who described the humanitarian community in Gaza as working relentlessly to stop the spread of polio, "a disease that the world thought it had under control". She added: "I don't need to tell you how disastrous it would be if we were unable to contain this preventable disease — a disease that knows no borders." Noting that Israel has facilitated the entry of all requested polio vaccines and equipment, she said: "What is now most important is to ensure both the security and access needed to implement the campaign effectively."...

::::::

mpox

<u>UNICEF issues emergency tender to secure mpox vaccines for crisis-hit countries in</u> collaboration with Africa CDC, Gavi and WHO

NEW YORK/COPENHAGEN, 31 August 2024 — UNICEF today announced that it has issued an emergency tender for the procurement of mpox vaccines...The UNICEF tender is issued to help secure mpox vaccines for the hardest hit countries in collaboration with Africa CDC, Gavi, the Vaccine Alliance, WHO, the Pan American Health Organization and other partners.

This collaboration to increase access and timely allocation also **includes working together to facilitate donations of vaccines from existing stockpiles in high-income countries** with the aim of containing the ongoing transmission of mpox.

Under the emergency tender, UNICEF will set up conditional supply agreements with vaccine manufacturers. This will enable UNICEF to purchase and ship vaccines without delay once countries and partners have secured financing, confirmed demand and readiness, and the regulatory requirements for accepting the vaccines are in place. WHO is currently reviewing the information submitted by manufacturers on 23 August and is expected to complete its review for Emergency Use Listing by mid-September.

More than 18,000 suspected cases of mpox, including 629 deaths, have been reported this year in the **Democratic Republic of the Congo which is at the epicentre of the crisis. Four out of five deaths have been in children.**

"Addressing the current mpox vaccine shortage and delivering vaccines to communities who need them now is of paramount importance. There is also a pressing need for a universal and transparent allocation mechanism to ensure equitable access to mpox vaccines," said Director of UNICEF Supply Division Leila Pakkala.

"As we confront the ongoing Mpox outbreak, the timely procurement and distribution of vaccines is crucial to protecting the most vulnerable populations, particularly in the hardest-hit regions. This emergency tender is a critical step forward in our collective effort to control the spread of this disease. Africa CDC is committed to ensuring that vaccines are allocated swiftly and equitably across the continent, in partnership with UNICEF, Gavi, WHO, and other key stakeholders. Our unified response is essential to curbing the impact of this public health emergency and safeguarding the health and well-being of our communities," said Dr. Jean Kaseya, Director General of Africa CDC.

"With several partners working on securing access to supply, today's announcement represents an important step in this emergency, enabling UNICEF to purchase and deliver vaccines after Gavi and other partners make funding available and sign purchase or donation agreements with manufacturers for the most immediate dose needs," said Dr Derrick Sim, interim Chief Vaccine Programmes and Markets Officer at Gavi, the Vaccine Alliance. "Securing access to supply and financing, delivering doses, and in parallel ensuring countries are ready to administer them, are all vital actions that need to be conducted rapidly but thoroughly, and in a coordinated manner. We welcome this tender as another positive step our Alliance and Africa CDC are taking in this response."

"A swift, coordinated, and equitable response is critical to controlling the current mpox emergency and preventing future ones," said Dr Maria Van Kerkhove, WHO incident manager for the global mpox response and acting Director for Epidemic and Pandemic Preparedness and Prevention. "All of us must act decisively now or risk allowing mpox to spread further and become an even greater global threat. In an interconnected world, the fight against mpox — as with other infectious diseases and health threats — cannot be waged alone., WHO is glad to partner with UNICEF, Gavi, Africa CDC, other partners and affected countries to get life-saving tools to people in need."

The emergency tender is designed to secure immediate access to available mpox vaccines as well as to expand production. Depending on demand, production capacity of manufacturers and funding, agreements for up to 12 million doses through 2025 can be put in place...

::::::

Africa CDC Media Advisory: Special Press Briefing on the Mpox Outbreak and Other Health Emergencies in Africa

30 August 2024

WHAT: Weekly engagement with the media to provide updates on the Mpox outbreak situation in DRC and other affected Member States. Africa CDC Director General, H.E. Dr Jean Kaseya, will share the latest insights and urgent actions being taken to combat the outbreak.

WHEN: Tuesday, 3rd September 2024

TIME: 16:00 Hrs – 17:30 Hrs | East Africa Time (+3 GMT) 14:00 Hrs – 15:30 Hrs | Central Africa Time (+1 GMT)

WHERE: Virtually, via zoom link below:

https://africacdc-org.zoom.us/webinar/register/WN fJHIMD8wTjGs3bLNk3vsyw

SPEAKER: H.E. Dr Jean Kaseya, Director General, Africa CDC Live stream: https://www.youtube.com/watch?v=hq9SqVMv2S0

Mpox outbreaks in Africa constitute a public health emergency of continental security 21 August 2024

WHO Director-General declares mpox outbreak a public health emergency of international concern

14 August 2024 News release

::::::

WHO - <u>Disease Outbreak News (DONs)</u>
30 August 2024 | Mpox - Sweden

22 August 2024 | Mpox - African Region

::::::

Mpox outbreak raises alarm in Eastern and Southern Africa as cases increase among children – UNICEF

NAIROBI, 22 August 2024 – Children and vulnerable communities are at the sharp end of an expanding outbreak of mpox in Eastern and Southern Africa. More than 200 confirmed cases have been detected across five countries (Burundi, Rwanda, Uganda, Kenya, South Africa), UNICEF reported today. The new variant of the mpox virus (clade Ib) has been...

<u>Children at significant risk from surging mpox outbreak in the Democratic Republic of the Congo - UNICEF</u>

KINSHASA/DAKAR, 16 August 2024 – Thousands of children in the Democratic Republic of the Congo (DRC) and neighbouring countries are at significant risk of contracting the mpox virus as cases of a new, more deadly, variant continue to surge, UNICEF warned today. Since the start of the year, an estimated 8,772 children have contracted the disease in...

::::::

Gavi statement on mpox emergency in Africa

Geneva, 15 August 2024 – Gavi, the Vaccine Alliance continues to be deeply concerned about the escalating mpox emergency on the African continent. We welcome recently announced measures by our partners at the African Centres for Disease Control and Prevention (Africa CDC) and World Health Organization (WHO) which will help create an enabling environment in support of a comprehensive region-led response, and join partners in emphasizing the importance of international coordination following a declaration of a Public Health Emergency of Continental Security by <u>Africa CDC</u> and a Public Health Emergency of International Concern by <u>WHO</u>.

Working in collaboration with countries and partners, Gavi has been closely monitoring the mpox situation since 2022. As a result, considerations related to mpox have helped inform both the design of Gavi's new innovative health security mechanisms, aimed at addressing systemic gaps exposed during the COVID-19 vaccine response, as well as Gavi's next five-year strategy. When the assessment process for Gavi's next five-year Vaccine Investment Strategy (VIS) began in 2023, mpox vaccines were included for consideration. Special sessions of the VIS Steering Committee were convened in Q1 2024 to ensure the approach took into account developments in the Democratic Republic of the Congo (DRC), where the outbreak has spread rapidly, primarily impacting children (in terms of both morbidity and mortality), and resulting in a high case fatality ratio.

As a result, in June 2024 the Gavi Board approved the following measures related to mpox:

- In its next five-year strategic period, beginning 2026, Gavi will establish a global stockpile of mpox vaccines similar to its existing stockpiles for cholera, Ebola, meningitis and yellow fever vaccines. Establishment of a stockpile is pending the availability of WHO Emergency Use Listing or prequalification of a recommended vaccine, and subject to fundraising for Gavi's next strategic period. A critical goal will be ensuring the design of the stockpile is informed by a robust assessment of the long-term public health need.
- In the interim, Gavi will support outbreak response in the DRC and surrounding countries. More details on this are available below.
- In parallel, Gavi will make critical investments in a learning agenda that will ensure the current response will help inform and improve future vaccination efforts against the disease, including the design of a global stockpile. More details on this are available below.

Gavi has been monitoring the mpox situation daily for the past several weeks, and is currently engaging closely with countries, Africa CDC, WHO, UNICEF, donors, and manufacturers to support the response to mpox. Our actions include:

- Rapid operational support: As an immediate measure, Gavi has formally declared the mpox situation a regional emergency and has initiated a process to expand this to the region. This allows us to trigger certain additional flexibilities and streamline processes, underpinned by a no-regrets approach to risk. Specifically, this could enable repurposing available funds in support of vaccine response (for example, funding for operational costs to support use of dose donations) and waiving of the formal independent review process for new vaccine introductions and campaigns.
- Leveraging new innovative mechanisms to support the overall response: In June 2024, the Gavi Board also approved the final terms of the <u>First Response Fund</u>, the fastest tool in a suite of instruments called the Day Zero Financing Facility, which in response to a key learning from COVID-19 seeks to make resources immediately available for a vaccine response to an urgent public health emergency. Gavi could draw on the First Response Fund, which can be accessed in the event of a WHO declaration of a Grade 2 or Grade 3 emergency or PHEIC, to support both direct procurement of mpox vaccines as well as country readiness and other aspects of the vaccine response.
- Direct procurement: Gavi has accelerated engagement with manufacturers, including Bavarian Nordic, for potential direct procurement of mpox vaccines in support of outbreak response. WHO has recently announced that two vaccines are under consideration for Emergency Use Listing, and this is an important interim measure enabling partners to act now, in advance of the longer timeframe expected for WHO prequalification.
- Dose donations and emergency response: Building on the unique experience of working with 33 donors to coordinate the supply of nearly 1 billion dose donations to 114 countries in response to COVID-19, Gavi will offer direct support and share knowledge with countries and partners as requested, while working with them on designing in-country vaccination strategies. In a workshop last month, the Government of DRC, Africa CDC, Gavi, WHO, UNICEF, and other partners worked together to design a three-phase vaccine response strategy, informed by a collective understanding of the available supply of dose donations. In parallel, Gavi is offering to share legal and process knowledge and provide operational support to Africa CDC and other partners who are also engaged in sourcing dose donations. Based on our experience working with donors, countries and partners to coordinate the global COVAX dose donation mechanism, this includes providing information on the complex technical, legal, regulatory and logistical considerations involved in mounting rapid vaccination campaigns with donated doses.
- Investing in a learning agenda: Following the June 2024 Board decision, Gavi has moved to ensure any vaccine response for mpox will also help improve the data available on disease burden and epidemiology, including through supporting surveillance studies and modelling studies on vaccine use and impact. Expanding the available data will support the work of countries and partners such as WHO and Africa CDC, and ensure a future global stockpile accurately addresses the longer-term public health need thus helping improve future vaccination efforts against the disease. Following recent developments, Gavi is in the process of working with partners to finalise the design of this agenda, with the aim issue a Request for Proposals as soon as possible.

_ __

::::::

Polio - PHEIC

Polio this week as of 28 August 2024 - GPEI

Summary of new polioviruses this week, cases and positive environmental isolates:

- Afghanistan: four WPV1 cases

- Pakistan: two WPV1 cases and 16 positive environmental samples
- Chad: two cVDPV2 cases and two positive environmental samples
- Côte d'Ivoire: two cVDPV2 positive environmental samples
- DR Congo: one cVDPV2 case
- Niger: one cVDPV2 positive environmental sample
- Nigeria: three cVDPV2 cases and one positive environmental sample
- occupied Palestinian territory: one cVDPV2 case
- South Sudan: one cVDPV2 case

::::::

Statement of the Thirty-ninth Meeting of the Polio IHR Emergency Committee

13 August 2024 Statement [Excerpt]

...Conclusion

The Committee unanimously agreed that the risk of international spread of poliovirus still remains a Public Health Emergency of International Concern (PHEIC) and recommended the extension of Temporary Recommendations for a further three months. The Committee considered the following factors in reaching this conclusion:

Ongoing risk of WPV1 international spread:

Based on the following factors, the risk of international spread of WPV1 remains:

- Spread of WPV1 transmission back into formerly endemic areas and core reservoirs of Afghanistan (Kandahar) and Pakistan (Karachi, Peshawar, Quetta Block), that represents a significant risk to the gains made during the last two years.
- The WPV1 transmission has essentially re-established in Kandahar (Afghanistan) and Peshawar (Pakistan).
- This epidemiological context is particularly concerning at the outset of high transmission season in both endemic countries.
- Despite overall resumption of house-to-house vaccination campaigns in Southern
 Afghanistan, Kandahar province continues to implement site-to-site or mosque-tomosque campaigns, which has been shown to be less effective than the house-to-house
 strategy;
- Certain geographies and population pockets in the epidemiologically critical areas of Pakistan continue to have inconsistent campaign quality and substantial number of unimmunized and under-immunized children
- High-risk mobile populations in Pakistan represent a specific risk of international spread to Afghanistan in particular, compounded by ongoing significant movement the returnees from Pakistan into a number of provinces of Afghanistan;
- Any setback in Afghanistan poses a risk to the programme in Pakistan due to high population movement.

Ongoing risk of cVDPV international spread:

Based on the following factors, the risk of international spread of cVDPV2 appears to remain high although numbers of cVDPV1 cases have gone down:

- Ongoing cross border spread including into newly re-infected countries such as Ethiopia and Equatorial Guinea
- Continued cVDPV2 transmission in the critical areas of Nigeria, with more than 40% of the global cVDPV2 cases in 2024 and it's potential to amplify the transmission

- The cVDPV2 transmission in the Horn of Africa seems to be intensifying during the first half of 2024. The Horn of Africa countries continue to face humanitarian and health emergencies making it very challenging to implement high-quality vaccination campaigns in a timely manner.
- There is a large pool of unimmunized susceptible children in the Northern Governorates of Yemen
- Despite the decreasing number of cVDPV cases, the transmission continues to be detected in DR Congo, as recent as April 2024 for cVDPV1 and March 2024 for cVDPV2
- The ever-widening gap in population intestinal mucosal immunity in young children since the withdrawal of OPV2 in 2016 and consequently high concentration of zero dose children in certain areas;
- Insecurity in many areas that are the source of cVDPV transmission.

Contributing factors include:

- Weak routine immunization: Many countries have weak immunization systems that can be further impacted by humanitarian emergencies including conflict and protracted complex emergencies. This poses a growing risk, leaving populations in these fragile states vulnerable to polio outbreaks.
- Lack of access: Inaccessibility continues to be a major risk, particularly in northern Yemen and Somalia which have sizable populations that have been unreached with polio vaccine for extended periods of more than a year.

...Based on the current situation regarding WPV1 and cVDPVs, and the reports provided by affected countries, the **Director-General accepted the Committee's assessment and on 12 continues to constitute a PHEIC with respect to WPV1 and cVDPV.** The Director-General endorsed the Committee's recommendations for countries meeting the definition for 'States infected with WPV1, cVDPV1 or cVDPV3 with potential risk for international spread', 'States infected with cVDPV2 with potential risk for international spread' and for 'States previously infected by WPV1 or cVDPV within the last 24 months' and extended the Temporary Recommendations under the IHR to reduce the risk of the international spread of poliovirus, effective, 12 August 2024.

.....

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

::::::

WHO & Regional Offices [to 31 Aug 2024]

https://www.who.int/news Selected News/Announcements/Statements 29 August 2024 News release WHO urges rapid access to mpox diagnostic tests, invites manufacturers to emergency review

28 August 2024 News release

WHO and International Paralympic Committee team up to highlight power of assistive technology at Paris 2024 Paralympics

27 August 2024 News release

Fourteen African countries, key partners unite to provide critical resources for health in WHO's first-ever Investment Round

26 August 2024 News release

Global strategic preparedness and response plan launched by WHO to contain mpox outbreak

19 August 2024 Statement

<u>First meeting of the International Health Regulations (2005) Emergency Committee</u> <u>regarding the upsurge of mpox 2024</u>

16 August 2024 Statement

Humanitarian pauses vital for critical polio vaccination campaign in the Gaza Strip

14 August 2024 News release

WHO Director-General declares mpox outbreak a public health emergency of international concern

13 August 2024 Statement

Statement of the Thirty-ninth Meeting of the Polio IHR Emergency Committee

::::::

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region

:: Intensifying efforts to end TB in South Africa

27 August 2024

Pretoria – One night in September 2023, 21-year-old university student Sinalo Tungwashe, who had been experiencing flu-like symptoms for some weeks, was roused from a fitful sleep by sharp chest pains. "I was struggling to breathe," he recalls. "I knew that something was not normal. For a second, I thought I was about to die."

:: Equatorial Guinea steps up screening to eradicate tuberculosis

26 August 2024

Malabo – Equatorial Guinea has made remarkable progress in its fight against tuberculosis (TB), with screening rates increasing significantly from 34% to 87% between 2020 and 2023. This progress is thanks to the implementation of a national strategy supported by World Health Organization (WHO) and the adoption of cutting-edge diagnostic tools.

:: Burundi adopts community-based approach to prevent mother-to-child transmission of HIV...

21 August 2024

Bujumbura – "It's unacceptable that in 2024, children are still born with HIV," says Novela Irakoze, a woman living who with HIV and advocate for prevention of mother-to-child transmission of HIV. "I was born with HIV and my goal is to protect children from experiencing what I did."

Novela is part of a group called Mentor Mothers, which supports pregnant women living with HIV in receiving treatment to protect their babies from HIV.

:: <u>Integrating female cancer screening into primary health care in Niger</u> 19 August 2024

Niamey – In Niger, efforts are underway to mainstream screening for gynaecological cancers into primary health care services thanks to the WHO PEN approach, a WHO programme that aims to integrate the management of noncommunicable diseases (NCDs) into basic health care. This initiative, in its pilot phase, is being carried out in Mayahi District, Maradi Region, in the centre south of the country.

:: Enhancing HPV vaccination to protect girls against cervical cancer in Lesotho
19 August 2024

"It was a no-brainer," says 34-year-old 'Malihaelo Qhobela of her decision to allow her 13-year-old daughter, Lihaelo, to be vaccinated against human papillomavirus (HPV) at Soofia International School in Lesotho's Butha-Buthe District.

WHO Region of the Americas PAHO

:: 16 Aug 2024

<u>PAHO and the Latin American Society of Pediatric Infectious Diseases join forces to reduce</u> childhood infectious diseases

San Jose, Costa Rica, August 16, 2024 (PAHO). The Pan American Health Organization (PAHO) and the Latin American Society of Pediatric Infectious Diseases (SLIPE) signed a cooperation agreement today aimed at reducing infectious diseases prevalent among children and adolescents in Latin America. Despite a 60% decrease in deaths among children...

:: 15 Aug 2024

<u>PAHO and IDB launch tool to assess countries' readiness to integrate Artificial Intelligence into healthcare systems</u>

Washington, DC, August 15, 2024 (PAHO) - The Pan American Health Organization (PAHO) and the Inter-American Development Bank (IDB) recently launched the Artificial Intelligence (AI) in Public Health: Readiness Assessment Toolkit, a tool that enables countries to optimize their capacity to integrate AI into public health systems. The...

:: 9 Aug 2024

<u>Countries of the Americas should strengthen Mpox surveillance in light of potential spread of new variant detected in African region, PAHO says</u>

Washington D.C. 9 August 2024 (PAHO/WHO) – In an epidemiological alert released on 8 August, the Pan American Health Organization (PAHO) has called on countries of the Americas to strengthen surveillance, including laboratory detection and genomic sequencing of confirmed cases, following the identification of a new variant of mpox virus,...

WHO South-East Asia Region SEARO

:: Regional consultation on Draft Global Strategy for traditional medicine 2025:2034 and to set the regional research priorities for WHO SEA region

20 August 2024 News release Bangkok

WHO European Region EURO

:: 20 August 2024 Statement

<u>Statement – Mpox: test for global equity and call for elimination in the European Region</u> :: 19 August 2024 News release

<u>Grim milestone on World Humanitarian Day: WHO records 1940 attacks on health care in Ukraine since start of full-scale war</u>

WHO Eastern Mediterranean Region EMRO

No new digest content identified.

WHO Western Pacific Region

:: 30 August 2024 News release

WHO calls on Pacific leaders to make health and climate a high priority at regional leaders' meeting

:: 23 August 2024 News release

<u>Pacific experts agree to further strengthen collaboration to protect communities from future outbreaks and pandemics</u>

::::::

WHO - Emergency situation reports

Latest WHO official reports for emergency situations.

22 August 2024

<u>Public Health Situation Analysis: Sudan Conflict – Refugee crisis in neighbouring countries</u> (20 August 2024)

22 August 2024

<u>Sudan conflict and refugee crisis, Multi-country External Situation Report #3, covering the reporting period July 2024</u>

16 August 2024

WHO's Operational Update on Health Emergencies - July 2024

15 August 2024

Multi-country outbreak of cholera, External situation report #17 - 15 August 2024

12 August 2024

Multi-country outbreak of mpox, External situation report#35- 12 August 2024

::::::

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

30 August 2024 | Mpox - Sweden

23 August 2024 | Oropouche virus disease - Region of the Americas

23 August 2024 | Acute encephalitis syndrome due to Chandipura virus - India

22 August 2024 | Mpox - African Region

::::::

Weekly Epidemiological Record

https://www.who.int/publications/journals/weekly-epidemiological-record

Vol. 99, Nos. 35, pp. 457-478 30 August 2024

PDF: https://iris.who.int/bitstream/handle/10665/378642/WER9935-eng-fre.pdf

:: WHO's Health Emergencies Programme: acute emergencies monthly summary – July 2024

:: Global yellow fever update, 2023

:::::

New WHO Publications

https://www.who.int/publications/i

Selected

28 August 2024

<u>Practical interim guidance to reduce the risk of infection in people exposed to avian</u> influenza viruses

27 August 2024

Ebola and Marburg disease outbreaks: infection prevention and control research priorities in health care...

26 August 2024

<u>Positive practices in developing primary health care-oriented health systems – A collection</u> of case stories...

23 August 2024

Smallpox and mpox (orthopoxviruses): WHO position paper, August 2024

22 August 2024

Report on South-East Asia Regional Working Group on Immunization

21 August 2024

Weekly Epidemiological Record, 2024, vol. 99, 09

21 August 2024

Weekly Epidemiological Record, 2024, vol. 99, 32

21 August 2024

WHO SEAR 17th Epidemiological Bulletin 2024

20 August 2024

Tobacco and HIV

20 August 2024

Expanded programme on Immunization (EPI) factsheet 2024: Thailand

20 August 2024

Expanded programme on Immunization (EPI) factsheet 2024: DPR Korea

20 August 2024

Expanded programme on Immunization (EPI) factsheet 2024: Bangladesh

20 August 2024

Expanded programme on Immunization (EPI) factsheet 2024: SEAR

20 August 2024

Expanded programme on Immunization (EPI) factsheet 2024: Bhutan

20 August 2024

Expanded programme on Immunization (EPI) factsheet 2024: Maldives 20 August 2024 Expanded programme on Immunization (EPI) factsheet 2024: Sri Lanka 20 August 2024 **Expanded programme on Immunization (EPI) factsheet 2024: Timor-Leste** 20 August 2024 Expanded programme on Immunization (EPI) factsheet 2024: India 20 August 2024 **Expanded programme on Immunization (EPI) factsheet 2024: Indonesia** 20 August 2024 **Expanded programme on Immunization (EPI) factsheet 2024: Myanmar** 20 August 2024 Expanded programme on Immunization (EPI) factsheet 2024: Nepal 19 August 2024 Implementation playbook: delivering impact for health 19 August 2024 Key updates to the treatment of drug-resistant tuberculosis: rapid communication, June 2024 16 August 2024 Global guidance on monitoring public health and social measures policies during health emergencies 15 August 2024 Planning for health system recovery: guidance for application in countries 14 August 2024 Myanmar Acute Watery Diarrhea / Cholera Outbreak External Situation Report 14 August 2024 Target product profile for tuberculosis diagnosis and detection of drug resistance :::::: :::::: **USA – HHS, FDA, CDC HHS** News

HHS Launches National Public Education Campaign Ahead of Respiratory Virus Season August 19, 2024 News Release

United States Government's Response to the Clade I Mpox Outbreak in the Democratic Republic of the Congo and Other Countries in the Region

August 14, 2024 News Release

...The United States Government has been closely monitoring the spread of clade I mpox in the DRC and neighboring countries since 2023, and we have been working closely with the Government of DRC, as well as regional and global health partners to reduce the impact of this outbreak and safeguard public health. U.S. government support for the mpox response also builds on our robust, longstanding health partnerships with DRC and throughout Africa, which have helped combat infectious diseases such as HIV, tuberculosis, and malaria for over 20 years. In fiscal year 2023, the United States allocated more than \$2.65 billion in bilateral health funding in Central and Eastern Africa. This response also builds on a longstanding partnership on global health security - PDF between DRC and the United States.

In addition to ongoing health support, in the last few months the United States has provided an additional \$17 million USD to support clade I mpox preparedness and response efforts in Central and Eastern Africa. The funding has enabled stronger surveillance, risk communication, and community engagement, as well as needed laboratory supplies and diagnostics, clinical services, and vaccine planning.

Vaccination will be a critical element of the response to this outbreak. To support this effort, the United States is donating 50,000 doses of the Food and Drug Administration (FDA)-approved JYNNEOS vaccine to DRC. The United States is working with other countries, WHO, and international partners to encourage donations that support vaccine efforts and address challenges to vaccine delivery...

FDA

Press Announcements

August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

...Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of age and older. It includes a monovalent (single) component that corresponds to the Omicron variant JN.1 strain of SARS-CoV-2...

August 30, 2024 - FDA Roundup: August 30, 2024

:: Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of age and older. It includes a monovalent (single) component that corresponds to the Omicron variant JN.1 strain of SARS-CoV-2.

August 22, 2024 - FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants

Today, the U.S. Food and Drug Administration approved and granted emergency use authorization (EUA) for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent (single) component that corresponds to the Omicron variant KP.2 strain of SARS-CoV-2. The mRNA COVID-19 vaccines have been updated with this formula to more closely target currently circulating variants and provide better protection against serious consequences of COVID-19, including hospitalization and death. Today's actions relate to updated mRNA COVID-19 vaccines manufactured by ModernaTX Inc. and Pfizer Inc...

FDA VRBPAC

Advisory Committee Calendar

<u>Vaccines and Related Biological Products Advisory Committee September 20, 2024</u> <u>Meeting Announcement - 09/20/2024</u>

CDC/ACIP [U.S.] [to 31 Aug 2024]

http://www.cdc.gov/media/index.html

Latest News

Aug 28, 2024

<u>Biden-Harris Administration Awards Over \$558 Million to Improve Maternal Health, including \$440 Million to Support Pregnant and New Moms, Infants, and Children through Voluntary Home Visiting Programs Proven to Improve Maternal and Child Health, Child Development, and School Readiness</u>

FACT SHEET: United States Response to the Clade I Mpox Outbreak in Several African
Countries United States Response to the Clade I Mpox Outbreak in Several African
Countries Aug 22, 2024

ACIP Meetings

Next ACIP Meeting October 23-24, 2024

MMWR Weekly

https://www.cdc.gov/mmwr/index2023.html

August 29, 2024 / No. 34

PDF of this issue

- <u>Cluster of Influenza A(H5) Cases Associated with Poultry Exposure at Two Facilities — Colorado, July 2024</u>

August 22, 2024 / No. 33

PDF of this issue

- <u>National Vaccination Coverage Among Adolescents Aged 13–17 Years National Immunization</u> Survey-Teen, United States, 2023
- <u>Human Papillomavirus Vaccination Coverage Among Adolescent Girls Aged 13–17 Years U.S.-</u> <u>Affiliated Pacific Islands, 2013–2023</u>
- <u>Vital Signs: Trends and Disparities in Childhood Vaccination Coverage by Vaccines for Children Program Eligibility National Immunization Survey-Child, United States, 2012–2022</u>

•	•	•	•	•	•	
:	:		:		•	

Europe

European Medicines Agency [EMA]

https://www.ema.europa.eu/en/news News & Press Releases No new digest content identified.

European Centre for Disease Prevention and Control

https://www.ecdc.europa.eu/en
News/Updates/Reports/Publications [Selected]
Assessment

Mpox and Substances of Human Origin

28 Aug 2024

MPXV has been detected in blood, urine, tissue abscesses and bodily fluids and could potentially be transmitted through SoHO. However, to date, there has been no reported transmission of MPXV through SoHO and the likelihood of this is unknown.

Epidemiological update: Mpox due to monkeypox virus clade I

26 Aug 2024

::::::

Africa CDC [to 31 Aug 2024]

https://africacdc.org/

Press Releases, Statements [Selected]

Media Advisory: Special Press Briefing on the Mpox Outbreak and Other Health

Emergencies in Africa

30 August 2024

Announcements

Mpox Research and Innovation – Aligning Research Response with Outbreak Goals

27 August 2024

Date: August 29-30th, 2024 (Hybrid Meeting)

Press Releases

Boost for Mali Immunization Programs

BAMAKO, Mali, August 23, 2024 – Mali's capacity to store and distribute vaccines safely, ensuring the continued success of both COVID-19 vaccination efforts and routine immunization programs was boosted with a donation of storage equipment worth over \$609,000 on August 16.

The Africa CDC in partnership with the Mastercard Foundation through the Saving Lives and Livelihood (SLL) program, handed over Cold Chain Equipment (CCE) to the Ministry of Health and Social Protection of Mali...

Biography

2024 Cohort of the Kofi Annan Fellowship in Global Health Leadership

22 August 2024

Articles

Mpox outbreaks in Africa constitute a public health emergency of continental security

21 August 2024

::::::

China CDC

http://www.chinacdc.cn/en/

National Health Commission of the People's Republic of China [to 31 Aug 2024]

http://en.nhc.gov.cn/

News

No new digest content identified.

National Medical Products Administration – PRC [to 31 Aug 2024]

http://english.nmpa.gov.cn/

News

COVID-19 infections not problematic, experts say

2024-08-15

The number of people in China being infected with COVID-19 is fluctuating reasonably and won't be a burden on medical resources or the public, experts said.

China CDC

CCDC Weekly Reports: Current Volume (6)

2024-08-30 / No. 35

View PDF of this issue

- Preplanned Studies: A Modeling Study Recurrent Tuberculosis Towards End TB Strategy China, 2025–2035
- <u>Preplanned Studies: Effectiveness of C-Reactive Protein as a Tuberculosis Screening Test Among HIV-Infected Individuals Shanghai, China, 2021–2023</u>
- <u>Perspectives: The Implications of Artificial Intelligence on Infection Prevention and Control: Current Progress and Future Perspectives</u>

::::::

Contents [click to move among sections]

:: Milestones, Perspectives

:: WHO

:: Organization Announcements

:: Journal Watch

:: Pre-Print Servers

::::::

Organization Announcements

Paul G. Allen Frontiers Group [to 31 Aug 2024]

https://alleninstitute.org/news-press/

News

Allen Institute scientists awarded \$1 million to research gene therapy for Dravet syndrome 08.20.2024

Washington Research Foundation grant will accelerate gene therapy development for the rare, devastating disorder.

BMGF - Gates Foundation [to 31 Aug 2024]

https://www.gatesfoundation.org/ideas/media-center

Press Releases & Statements

Statement from CEO Mark Suzman on the mpox public health emergency

August 20, 2024

... It is heartening to see many regional and global institutions ramp up their support in response to the public health emergency declarations by the Africa Centres for Disease Control and Prevention (Africa CDC) and the World Health Organization. The Bill & Melinda Gates Foundation is supporting the African researchers leading the response and the work they're doing to leverage existing disease surveillance and early warning systems to inform national and regional public health decision-making. Guided by the continued leadership of mpox-affected country governments, organizations like the

Africa CDC, Gavi, the Vaccine Alliance, and the Coalition for Epidemic Preparedness Innovations (CEPI) are taking action to increase access to the vaccines needed to save lives now.

As the global effort to get this outbreak under control moves forward, our foundation will continue to support the critical work of our partners around the world and call on governments and organization...

Bill & Melinda Gates Medical Research Institute [to 31 Aug 2024]

https://www.gatesmri.org/news

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

News: Articles and Publications No new digest content identified.

CARB-X [to 31 Aug 2024]

https://carb-x.org/

News

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [to 31 Aug 2024]

http://cepi.net/

CEPI News

Blog

The quest to detect the next pandemic threat

Global experts discuss the gaps and opportunities in global disease surveillance 28 Aug 2024

News

A Lassa vaccine is urgently needed to save thousands of lives

27 Aug 2024

News

CEPI partners with Afrigen to speed up mRNA vaccine development and access

26 Aug 2024

...In a US\$2.05 million CEPI-funded project, researchers at <u>Afrigen Biologics</u>, a South African biotech company that is home to the <u>mRNA Technology Transfer Programme</u>, will explore whether optimised synthetic DNA can help to reduce mRNA vaccine development timelines for emergency use in the event of a disease outbreak. The CEPI-Afrigen partnership supports the 100 Days Mission—a goal embraced by leaders of the G7 and G20 to reduce vaccine development timelines to a little over three months in response to a pandemic threat...

CIOMS - COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 31]

Aug 2024]

https://cioms.ch/

News; Publications; Events

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 31 Aug 2024

https://www.darpa.mil/news

News

No new digest content identified.

Duke Global Health Innovation Center [to 31 Aug 2024]

https://dukeghic.org/

News

No new digest content identified.

EDCTP [to 31 Aug 2024]

http://www.edctp.org/

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

No new digest content identified.

Emory Vaccine Center [to 31 Aug 2024]

http://www.vaccines.emory.edu/ Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 31 Aug 2024]

http://www.euvaccine.eu/ Latest News, Events No new digest content identified.

Evidence Aid [to 31 Aug 2024]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.

http://www.evidenceaid.org/

Resources [Selected]

Public health preparedness for infectious disease emergencies

Added August 27, 2024

Health effects of power outages in extreme events

Added August 27, 2024

Governance of childhood vaccination services in crisis settings

Added August 22, 2024

Fondation Merieux [to 31 Aug 2024]

http://www.fondation-merieux.org/

News, Events

No new digest content identified.

Gavi [to 31 Aug 2024]

https://www.gavi.org/

Press Releases 30 August 2024

<u>Central African Republic introduces new malaria vaccine in routine EPI to vaccinate around 200,000 children in 2024</u>

26 August 2024

African Union, Gavi and Japan unite to bolster health security and universal health coverage in Africa

15 August 2024

Gavi statement on mpox emergency in Africa

14 August 2024

ASEAN health ministers pledge boldly to boost immunization in the region

GE2P2 Global Foundation [to 31 Aug 2024]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

- :: Vaccines and Global Health: The Week in Review Current edition
- :: Informed Consent: A Monthly Review June 2024
- :: Public Consultations Watch :: Global Calls for Input/Public Comment 29 August Issue 22

GHIT Fund [to 31 Aug 2024]

https://www.ghitfund.org/newsroom/press

Press Releases

No new digest content identified.

Global Fund [to 31 Aug 2024]

https://www.theglobalfund.org/en/news/

News Releases

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 31 Aug

2024]

https://www.glopid-r.org/new s/

News

No new digest content identified.

Hilleman Laboratories [to 31 Aug 2024]

http://www.hilleman-labs.org/

News & Insights

Unique International Collaboration Brings Breakthrough Oral Cholera Vaccine to Market

Singapore-based Hilleman Laboratories, along with Bharat Biotech, confirm launch of new cholera vaccine, HILLCHOL®, marking significant public health milestone towards pre-qualification from the WHO for wider distribution globally

Singapore, August 27, 2024 – Hilleman Laboratories has today announced that its partner Bharat Biotech, has successfully launched HILLCHOL®, a breakthrough oral cholera vaccine (OCV), achieving a significant global public health milestone.

Singapore-based Hilleman Laboratories - a joint venture between MSD and Wellcome - is a first-ofits-kind vaccine development hub, focused on accelerated end-to-end research and the development of affordable vaccines for distribution in low- and middle-income countries (LMICs).

The launch of HILLCHOL® is a result of an innovative model of international partnership between Hilleman Laboratories and Bharat Biotech, an Indian multinational biotechnology company.

Today's announcement follows the successful completion of HILLCHOL® Phase III clinical trials and approval for licensure by Bharat Biotech in India. This is after Hilleman Laboratories developed the vaccine through Phase II clinical research before transferring the vaccine to Bharat Biotech, who now intends to pursue pre-qualification for the licensure of HILLCHOL® from the World Health Organization (WHO) for wider distribution globally.

From its vaccine and biologics development and manufacturing hub in Singapore, Hilleman Laboratories is currently developing a portfolio of vaccines that could benefit up to 500 million people in low- and middle-income countries over the next five years...

HHMI - Howard Hughes Medical Institute [to 31 Aug 2024]

https://www.hhmi.org/news

Press Room

HHMI Invests \$500 Million in AI-Driven Life Sciences Research

Centered at the Janelia Research Campus, AI@HHMI will embed AI systems throughout every stage of the scientific process in labs across HHMI over the next 10 years.

August 12, 2024

Human Immunome Project [nee Human Vaccines Project] [to 31 Aug 2024]

https://www.humanimmunomeproject.org/

News

No new digest content identified.

IAVI [to 31 Aug 2024] https://www.iavi.org/
News, Features
Features

First-ever Phase 2 Lassa vaccine clinical trial now fully active across West Africa

August 26, 2024

Researchers at three sites are vaccinating participants for Lassa fever, an emerging infectious disease with outbreaks in the region.

Scientific Publications

<u>Prevalence of human filovirus infections in sub-Saharan Africa: A systematic review and meta-analysis protocol</u>

INSERM [to 31 Aug 2024] https://www.inserm.fr/en/home/

Press Releases No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

http://www.icmra.info/drupal/en/news Selected Statements, Press Releases, Research No new digest content identified.

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 31 Aug 2024]

https://www.ich.org/ News/Pubs/Press Releases [Selective] 21 August 2024

The ICH E11A Guideline reaches Step 4 of the ICH Process

The E11A Guideline provides recommendations and promotes international harmonisation of paediatric extrapolation to support the development and authorisation of paediatric medicines. The E11A Guideline provides a framework for using extrapolation to support paediatric drug development. The framework describes an iterative process for understanding the existing information available, the gaps in information needed to inform development, and ways to generate additional information when required and recommends approaches to assessing factors that influence the determination of similarity of disease, drug pharmacology, and response to treatment between a reference and paediatric target population. In addition, it discusses how the characteristics of the disease, drug pharmacology and response to treatment may influence this determination.

ICRC [to 31 Aug 2024]

https://www.icrc.org/en/whats-new

What's New [Selected]

Israel and the Occupied Territories: International Day of the Disappeared

30-08-2024 Israel and the Occupied Territories (ICRC) – On the International Day of the Disappeared, our hearts are with Israeli, Palestinian and all other families enduring the agony of not knowing ... News release 30-08-2024

World Humanitarian Day: ICRC President on attacks against aid workers

19-08-2024 Today marks World Humanitarian Day. Last year was the deadliest on record for humanitarian workers globally, and 2024 is set to be worse. The following quote is attributed to ICRC News release 19-08-2024

Geneva Conventions 75th Anniversary: Reaffirm commitment to IHL and make it a political priority

Speech by Balthasar Staehelin, the personal envoy of the ICRC president to China and head of the Regional Delegation for East Asia, at the event to mark the 75th Anniversary of the Geneva Conventions ...

Statement 12-08-2024

ICRC President Mirjana Spoljaric: A human life is a human life

12-08-2024 In a speech at a media briefing on the 75th anniversary of the Geneva Conventions, ICRC President Mirjana Spoljaric calls for the world to recommit to the framework for armed conflict that ... News release 12-08-2024

ICRC President Mirjana Spoljaric: The world must recommit to the framework for armed conflict that follows the premise of protecting life

Speech given at media briefing on the 75th anniversary of the Geneva Conventions The Geneva Conventions are the foundational treaties of international humanitarian law and a remarkable success in

Statement 12-08-2024

Geneva Conventions 75th anniversary: Foundational treaties save lives and dignity, but massive humanitarian suffering shows the world must recommit

12-08-2024 ICRC President issues a call to make the Geneva Conventions a political priority Geneva (ICRC) – On the 75th anniversary of the Geneva Conventions of 12 August 1949, the president of the News release 12-08-2024

IFFIm

http://www.iffim.org/

Press Releases/Announcements

Strengthening Gavi's replenishment with IFFIm

29 Aug 2024

IFFIm allows countries to make an immediate, significant impact on Gavi's mission, while ensuring this innovative finance mechanism continues to benefit Gavi, donors, and partners.

<u>Lifesaving immunisation: progress made possible by IFFIm</u>

29 Aug 2024

A child in need of a life-saving vaccine cannot afford to wait. IFFIm employs a frontloading model that enables Gavi to protect people, communities and the world faster by bringing future aid forward to have an immediate impact.

IFRC [to 31 Aug 2024]

http://media.ifrc.org/ifrc/news/press-releases/

Press Releases [Selected] Press release 23/08/2024

IFRC announces CHF 40 million appeal as Africa faces surge in mpox cases

Kinshasa/Nairobi/Geneva – 23 August 2024 – The International Federation of the Red Cross and Red Crescent Societies (IFRC) has launched an CHF40 million regional emergency appeal to bolster mpox preparedness and response across Africa, with CHF 5 million provided through the IFRC Disaster Response Emergency Fund (IFRC-DREF) as a loan to this regional emergency appeal. This funding will help us reach 30 million people in countries with an active outbreak, including DRC and neighbouring countries at high risk of the virus spreading further...

Press release 16/08/2024

IFRC scales up mpox response in Africa as global health emergency declared

Institut Pasteur [to 31 Aug 2024]

https://www.pasteur.fr/en/press-area

Press Documents

Mpox outbreak: "We are ready to test and vaccinate"

Press release 2024.08.19

..[On] Thursday August 15, Sweden reported the first positive case of clade 1b mpox on European soil. This led the French government to place the French health system on maximum alert on Friday

August 16, and the French authorities have now begun to re-evaluate the health recommendations established in 2022 during the previous mpox outbreak in preparation for the probable emergence of cases in the country. In these circumstances, the Institut Pasteur is contributing to the national response by taking three immediate measures...

ISC / International Science Council [to 31 Aug 2024]

https://council.science/current/

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

The collapse of science: a scientist's personal account from Gaza

Publishing date: August 20, 2024

International Union of Immunological Societies (IUIS)

https://iuis.org/ News/Events [Selected] No new digest content identified.

IVAC [to 31 Aug 2024]

https://www.ihsph.edu/research/centers-and-institutes/ivac/index.html

Updates; Events

No new digest content identified.

IVI [to 31 Aug 2024]

http://www.ivi.int/

IVI News & Announcements

Jessica Cowden joins IVI as Associate Director General of the CARE unit

August 30, 2024 – SEOUL, Republic of Korea – We are pleased to announce that Jessica Cowden, MD, MPH, FAAP, has been appointed Associate Director General of IVI's Clinical, Assessment, Regulatory, Evaluation (CARE) unit. She will be based in IVI's Europe Regional Office in Stockholm, Sweden, effective September 1, 2024.

Johns Hopkins Center for Health Security [to 31 Aug 2024]

https://centerforhealthsecurity.org/newsroom Center News [Selected] No new digest content identified.

MSF/Médecins Sans Frontières [to 31 Aug 2024]

http://www.msf.org/

Latest [Selected Announcements]

Gaza-Israel war

With Al-Agsa hospital under threat, MSF opens field hospital in central Gaza

Press Release 28 Aug 2024

Gaza-Israel war

Displaced people struggle without sanitation services in Khan Younis, Gaza

Project Update 27 Aug 2024

Conflict in Sudan

<u>Soaring medical needs and a failing humanitarian response mark 500 days of war in Sudan</u> Press Release 27 Aug 2024

Chad

Rapid response needed in Koukou as thousands flee worst floods in living memory
Project Update 16 Aug 2024

Haiti

<u>People fleeing violence in Port-au-Prince urgently need water and sanitation</u> Project Update 15 Aug 2024

National Academy of Medicine - USA [to 31 Aug 2024]

https://nam.edu/programs/

News [Selected]

National Academy of Medicine Announces Inaugural Fellows in State Health Policy Fellowship Pilot Program

August 27, 2024

The National Academy of Medicine (NAM) today announced the inaugural class of fellows in a pilot State Health Policy Fellowship (SHPF) program. Starting in September, three health professionals will spend [...]

National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 31 Aug 2024]

https://www.nationalacademies.org/newsroom?

News

No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 31 Aug 2024]

https://www.hhs.gov/vaccines/about/index.html Upcoming Meetings/Latest Updates No new digest content identified.

NIH [to 31 Aug 2024] http://www.nih.gov/ News Releases No new digest content identified.

PATH [to 31 Aug 2024]

https://www.path.org/media-center/

Newsroom

New HPV vaccine from Zerun Bio receives WHO prequalification

August 29, 2024 by PATH

This important milestone will provide countries with an additional option for affordable HPV vaccination and will contribute to sustainable supply of HPV vaccine—ensuring more girls are reached by this lifesaving vaccine.

Walrinvax[™], a bivalent human papillomavirus (HPV) vaccine, has been prequalified by the World Health Organization (WHO). Walrinvax is manufactured by Yuxi Zerun Biotechnology Co., Ltd. in Yuxi City, Yunnan Province, China, a fully owned subsidiary of Shanghai Zerun Biotechnology under Walvax Biotechnology Co., Ltd. Walrinvax is designed to protect against HPV types 16 and 18, the most common virus types that lead to cervical cancer. Countries facing barriers to national introduction or struggling to expand their HPV vaccine program due to price or supply constraints will now have another option for affordable, sustainable access...

PATH has been providing technical assistance to Zerun Bio to support the product development and prequalification process since 2017. Activities included improving the quality management and pharmacovigilance systems and providing chemistry, manufacturing, and controls; quality; and clinical advice for the pregualification dossier.

"The prequalification of Walrinvax will help move the world closer to its HPV vaccination goals, and we are encouraged by Zerun and Walvax's commitment to serving the global market," says Yuan Yuan, PATH China country representative. "The addition of another HPV vaccine to the global toolkit will help ensure equitable vaccination for girls in low- and middle-income countries."...

Sabin Vaccine Institute [to 31 Aug 2024]

https://www.sabin.org/press/ Latest News & Press Releases Press Releases

Infectious Disease Expert Kelly Warfield Named Sabin's New R&D President

August 20, 2024

... A critical priority for Warfield will be to work with partners to bring Sabin's candidate vaccines against Marburg and Sudan ebolavirus diseases to licensure...

UNICEF [to 31 Aug 2024]

https://www.unicef.org/media/press-releases Latest press releases, news notes and statements News note 31 August 2024

<u>UNICEF issues emergency tender to secure mpox vaccines for crisis-hit countries in collaboration with Africa CDC, Gavi and WHO</u>

NEW YORK/COPENHAGEN, 31 August 2024 – UNICEF today announced that it has issued an emergency tender for the procurement of mpox vaccines. Vaccines can play a critical role in containing the mpox outbreak which was declared a public health emergency by both the Africa Centres for Disease Control and Prevention (Africa CDC) and the World Health...

Press release 30 August 2024

Two million children at risk as worst floods in three decades lash through eastern Bangladesh - UNICEF

DHAKA, 30 August 2024 – Over two million children in eastern Bangladesh are at risk as floods sweep through homes, schools and villages, UNICEF has warned. In all, these floods, the worst in eastern Bangladesh in 34 years, have affected 5.6 million people. Major rivers in the southeast are overflowing due to unprecedented monsoon rains. As a...

Press release 24 August 2024

<u>Seven years after forced mass displacement of Rohingya from Myanmar, deadly attacks on children continue in Rakhine State</u>

NEW YORK/KATHMANDU/BANGKOK, 25 August 2024 – Seven years after hundreds of thousands of Rohingya people fled violence and persecution in Myanmar, conflict continues to intensify in Rakhine State, on the western coast of Myanmar, with a surge in casualties and displacement in Maungdaw Township and reports of increasing numbers of people seeking...

Statement 22 August 2024

UNICEF statement on execution of four youths in Puntland state, Somalia

NEW YORK/NAIROBI, 22 August 2024 - UNICEF notes with deep regret the execution of four young people in the Somali state of Puntland this past weekend for offences committed as children when they were under the age of 18, while they were allegedly associated with Al Shabaab. The convictions and sentences were issued by military courts, which lack...

Press release 22 August 2024

Mpox outbreak raises alarm in Eastern and Southern Africa as cases increase among children – UNICEF

NAIROBI, 22 August 2024 – Children and vulnerable communities are at the sharp end of an expanding outbreak of mpox in Eastern and Southern Africa. More than 200 confirmed cases have been detected across five countries (Burundi, Rwanda, Uganda, Kenya, South Africa), UNICEF reported today. The new variant of the mpox virus (clade Ib) has been...

Press release 18 August 2024

Acute malnutrition surges in Government of Yemen-controlled areas with extremely critical conditions reported in West Coast areas

ADEN, Yemen, 18 August 2024 – Acute malnutrition is rapidly increasing in Government of Yemen (GoY)-controlled areas, with the West Coast experiencing "extremely critical" levels for the first time, the Integrated Food Security Phase Classification (IPC) Technical Working Group in Yemen said today. According to the latest IPC Acute Malnutrition...

Press release 16 August 2024

<u>Children at significant risk from surging mpox outbreak in the Democratic Republic of the Congo - UNICEF</u>

KINSHASA/DAKAR, 16 August 2024 – Thousands of children in the Democratic Republic of the Congo (DRC) and neighbouring countries are at significant risk of contracting the mpox virus as cases of a new, more deadly, variant continue to surge, UNICEF warned today. Since the start of the year, an estimated 8,772 children have contracted the disease in...

News note 16 August 2024

Humanitarian pauses vital for critical polio vaccination campaign in the Gaza Strip

JERUSALEM/CAIRO/AMMAN, 16 August 2024 – Two rounds of a polio vaccination campaign are expected to be launched at the end of August and September 2024 across the Gaza Strip to prevent the spread of circulating variant type 2 poliovirus (cVDPV2). WHO and UNICEF request all parties to the conflict to implement humanitarian pauses in the Gaza Strip...

Press release 13 August 2024

<u>Almost half a billion children live in areas experiencing at least twice as many extremely</u> hot days as their grandparents - UNICEF

NEW YORK, 14 August 2024 – One in 5 children – or 466 million – live in areas that experience at least double the number of extremely hot days every year compared to just six decades ago, according to a new UNICEF analysis. Using a comparison between a 1960s and a 2020-2024 average, the analysis issues a stark warning about the speed and scale at...

Unitaid [to 31 Aug 2024]

https://unitaid.org/ Featured News 29 August 2024

New Unitaid report: How to increase access to medical oxygen in low-resource settings

28 August 2024

<u>Unitaid announces new funding opportunity aimed at improving outcomes for children with severe anemia</u>

23 August 2024

WHO recommendations, supported by Unitaid clinical trials, now allow for better treatment for all people with drug-resistant TB, including children and pregnant women

21 August 2024

Mpox emergency response must prioritize access to diagnostics, clinical care and vaccines

21 August 2024

First Nigerian manufacturer obtains WHO prequalification for key malaria prevention drug

Vaccine Equity Cooperative [nee Initiative] [to 31 Aug 2024]

https://vaccineequitycooperative.org/news/

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin) [to 31 Aug 2024]

https://www.vaccineacceptance.org/

Announcements, Blog

No new digest content identified.

Vaccine Confidence Project [to 31 Aug 2024]

http://www.vaccineconfidence.org/

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children's Hospital of Philadelphia [to 31 Aug 2024]

http://www.chop.edu/centers-programs/vaccine-education-center

News

Vaccine Update Newsletter August 2024

Wellcome Trust [to 31 Aug 2024]

https://wellcome.org/news/all

News. Opinion, Reports

Research story

Author - Jan Holmgren

How vaccines and research can help prevent cholera outbreaks

29 August 2024

The Wistar Institute [to 31 Aug 2024]

https://www.wistar.org/news/press-releases

Press Releases

No new digest content identified.

World Bank [to 31 Aug 2024] http://www.worldbank.org/en/news/all All News [Selected] No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 31 Aug 2024]

https://www.wfpha.org/

Blog, Events

<u>Professor Raman Bedi Appointed as Vice President-President-Elect of the World Federation of Public Health Associations (WFPHA)</u>

News Aug 21, 2024

World Medical Association [WMA] [to 31 Aug 2024]

https://www.wma.net/news-press/press-releases/

Press Releases

WMA calls for governments' cooperation in mpox public health emergency

19th August 2024

The World Medical Association urges governments to adhere to the principles of the 2023 UN Political Declaration on <u>Pandemic Prevention</u>, <u>Preparedness</u>, <u>and Response</u> (PPPR), in response to the designation by the WHO of <u>mpox</u> as a public health emergency of international concern (PHEIC).

"As we face the mpox crisis, WMA calls on countries to enhance regional and international cooperation to deliver a united, multisector and high-level approach. We ask governments to guarantee the affordable, equitable, and timely access to mpox medical countermeasures. And so that no one is left behind during the mpox public health emergency, WMA encourages national governments to provide universal access to quality health services, without financial hardship, for everyone and particularly for those in vulnerable situations," said Dr. Lujain AlQodmani, President of the World Medical Association...

World Organisation for Animal Health [OIE] [to 31 Aug 2024]

https://www.oie.int/

Press Releases, Statements

Statements

WOAH statement on novel mpox

Published on 23 August 2024

... As of 23 August 2024, WOAH has not received any confirmed reports of MPXV clade 1b in animals. Although WOAH Members are required to officially notify listed diseases, and MPXV is not a listed disease, they are encouraged to inform WOAH about the identification of MPXV in animals.

WOAH is responding to this challenge by actively encouraging its Members to report confirmed cases of mpox in animals, as well as to take appropriate risk mitigation measures. To reduce the risk of human to animal transmission, WOAH has developed <u>quidance</u> for various risk groups. To raise

awareness on the topic, WOAH has also developed a set of <u>online resources</u> including prevention and diagnosis strategies for animals...

::::::

ARM [Alliance for Regenerative Medicine] [to 31 Aug 2024]

https://alliancerm.org/press-releases/ Selected Press Releases No new digest content identified.

BIO [to 31 Aug 2024]

https://www.bio.org/press-releases

Press Releases

BIO Statement On Selected Drugs in Medicare under Inflation Reduction Act

August 15, 2024

DCVMN – Developing Country Vaccine Manufacturers Network [to 31 Aug 2024]

http://www.dcvmn.org/
News; Upcoming events

ANNUAL GENERAL MEETING 2024

October 16 - 18, 2024 São Paulo, Brazil

ICBA – International Council of Biotechnology Associations [to 31 Aug 2024]

https://internationalbiotech.org/news/

News

No new digest announcements identified.

IFPMA [to 31 Aug 2024]

https://ifpma.org/

News, Statements [Selected]

Statement 29 Aug 2024

AMATA statement on the Framework for strengthening local production of medicines, vaccines, and other health technologies in the WHO African Region 2025-2035

On 29 August at the 74th WHO Africa Regional Committee Meeting in Brazzaville, Republic of Congo, the African Medicines Agency Treaty Alliance delivered a statement on Agenda item 10: Framework for strengthening local production of medicines, vaccines, and other health technologies in the WHO African Region 2025-2035.

Statement 28 August 2024

IFPMA statement on the Framework for strengthening local production of medicines, vaccines, and other health technologies in the WHO African Region 2025-2035

By IFPMA

On 28 August at the 74th WHO Africa Regional Committee Meeting in Brazzaville, Republic of Congo, IFPMA submitted a statement on Agenda item 10: Framework for strengthening local production of medicines, vaccines, and other health technologies in the WHO African Region 2025-2035.

International Alliance of Patients' Organizations – IAPO [to 31 Aug 2024]

https://www.iapo.org.uk/news Press and media [Selected] No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

https://www.igbamedicines.org/

News

No new digest announcements identified.

PhRMA [to 31 Aug 2024]

http://www.phrma.org/

Press Releases

PhRMA Statement on Government Price Setting in Medicare Part D

August 14, 2024

::::::

Vaccines/Therapeutics/Medicines - Selected Developer/Manufacturer Announcements

AstraZeneca

Press Releases - No new digest announcements identified.

Bavarian Nordic

Latest News

August 27, 2024 | Press Releases

Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Singapore

August 21, 2024 | Company Announcements

<u>Bavarian Nordic Receives 440,000 Dose Contract to Supply Smallpox and Mpox Vaccines</u> for Undisclosed European Country

August 17, 2024 | Press Releases

<u>Bavarian Nordic Provides Statement on Mpox Vaccine Supply and Collaboration with</u>
African and Global Stakeholders

..."Bavarian Nordic is working closely with all stakeholders to ensure the equitable access to our mpox vaccine during the current PHECS and PHEIC. Importantly, we have built a strong partnership with the Africa CDC, both on supply, but also expanding our manufacturing network to include Africa. We are also working with the WHO on a regulatory path to ensure access to all countries, while in parallel seeking approval for use in adolescents and conducting clinical studies in Africa to further expand the use to children. We are prepared to work with the Africa CDC and the international community to play our role in protecting and saving lives around the World and to contain the latest outbreak," said Paul Chaplin, President & CEO of Bavarian Nordic...

August 16, 2024 | Press Releases

Bavarian Nordic Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents

Bavarian Nordic Receives Order from HERA and Announces Significant Donation of Vaccines in Response to the Mpox Outbreak in Africa

August 13, 2024 | Company Announcements

Bavarian Nordic Announces FDA Acceptance and Priority Review of the BLA for its Chikungunya Vaccine

Bharat Biotech

Press Releases

Bharat Biotech Launches Next Generation Oral Cholera Vaccine HILLCHOL®; Expands Manufacturing to Address Global Shortage

Bharat Biotech is committed to make HILLCHOL® accessible and affordable for countries with the highest burden of disease.

- :: Bharat Biotech's collaboration with MSD, Wellcome-Trust Hilleman Laboratories aims to address the critical shortage of OCVs
- :: Global demand for Oral Cholera Vaccines (OCVs) exceeds 100 million doses annually, making them crucial for cholera control
- :: Globally, there is a shortage of OCVs as there is only one manufacturer. The deficit is ~40 million doses per year, Bharat Biotech plans to bridge this gap with its HILLCHOL® vaccine
- :: HILLCHOL®'s safety and efficacy have been rigorously tested in pre-clinical and Phase I and Phase II clinical studies
- :: A multi-stage clinical evaluation process, culminating in a Phase III study, confirmed the vaccine's safety, immunogenicity and non-inferiority to existing OCVs, establishing its potential for widespread public health use.

Hyderabad, India - August 27, 2024

BioCubaFarma – Cuba

<u>Últimas Noticias</u> - No new digest announcements identified

Biological E

News

BE RECEIVES WHO'S PQ FOR THEIR NOVEL ORAL POLIO VACCINE

nOPV2 is a next-generation oral vaccine developed to combat cVDPV2 outbreaks

Hyderabad, July 30, 2024: In a monumental stride towards eradicating polio worldwide, Biological E. Limited (BE), a Hyderabad-based vaccine and pharmaceutical company today announced that the World Health Organisation (WHO) has granted Pre-qualification (PQ) status to their Novel Oral Polio Vaccine type 2

BioNTech

Press Releases

22 August 2024

<u>Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine</u>

16 August 2024

<u>Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program</u>
<u>Against Influenza and COVID-19 in Individuals 18-64 Years of Age</u>

Boehringer

Press Releases

Boehringer Ingelheim announces appointments Board of Managing Directors

Ingelheim, Fri, 08/30/2024 - 14:15

- :: Carinne Brouillon, member of the Board of Managing Directors with responsibility for the Human Pharma Business Unit, to retire from Boehringer Ingelheim, effective October 1, 2024
- :: Shashank Deshpande, member of the Board of Managing Directors, appointed to lead the Human Pharma Business Unit, effective October 1, 2024
- :: Dr. Armin Wiesler appointed member of the Board of Managing Directors with responsibility for the Animal Health Business Unit, effective October 1, 2024

CanSinoBIO

News - Website not responding at inquiry

CIGB

<u>Latest News</u> - No new digest announcements identified.

Cinnagen

Recent News - No new digest announcements identified.

Clover Biopharmaceuticals – China

News - No new digest announcements identified.

Curevac

News

August 15, 2024

<u>CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients</u> with Resected Glioblastoma

August 15, 2024

<u>CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory</u>
Board

Gamaleya National Center/Sputnik

<u>Latest News and Events</u> - No new digest announcements identified [Last: 09 Nov 2020] <u>https://sputnikvaccine.com/</u> - No new digest announcements identified [Last: 31 Aug 2022]

GSK

Press releases for media

29 August 2024

<u>European Commission approves expanded age indication for GSK's Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk</u>

Authorisation helps protect this population for the first time ahead of this RSV season

EuBiologics, S Korea

News - No new digest announcements identified.

IMBCAMS, China

Home - Website not responding at inquiry.

Janssen/JNJ

<u>Press Releases</u> - No new digest announcements identified.

Merck

News releases - No new digest announcements identified

Moderna

Press Releases

August 29, 2024

Moderna Launches National Awareness Campaign to Help Drive COVID-19 Vaccination

August 23, 2024

Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R)

August 23, 2024

Ministry of Health, Labour and Welfare in Japan Approves Partial Change Application for Moderna's COVID-19 mRNA Vaccine Targeting SARS-COV-2 Variant JN.1

August 22, 2024

Celebrating U.S. FDA Approval of Our Updated COVID-19 Vaccine

August 22, 2024

Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant of SARS-CoV-2

Nanogen

News - No new digest announcements identified

Novartis

<u>News</u> - No new digest announcements identified.

Novavax

Press Releases

Aug 30, 2024

COVID-19

Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.

Aug 22, 2024

Statement COVID-19

Novavax Continues to Partner with the U.S. FDA on Review of 2024-2025 Formula COVID-19 Vaccine

Pfizer

Recent Press Releases

<u>Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted</u> COVID-19 Vaccine

08.22.2024 Vaccines

<u>Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program</u>
<u>Against Influenza and COVID-19 in Individuals 18-64 Years of Age</u>
08.16.2024 Vaccines

<u>Pfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults</u> August 12, 2024 -

:: First assessment from an RSV vaccine study in immunocompromised adults show ABRYSVO was well-tolerated and generated strong neutralizing responses after a single dose in adults \geq 18 years of age

:: These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV

R-Pharm

https://rpharm-us.com/index.php
[No news or media page identified]

Sanofi Pasteur

<u>Press Releases</u> - No new digest announcements identified

Serum Institute of India

<u>NEWS & ANNOUNCEMENTS</u> - No new digest announcements identified

Sinopharm/WIBPBIBP

<u>News</u> - No new digest announcements identified

Sinovac

Press Releases - No new digest announcements identified

SK Biosciences

Press Releases - No new digest announcements identified

Takeda

<u>Newsroom</u> - No new digest announcements identified.

Valneva

<u>Press Releases</u> - No new digest announcements identified

Vector State Research Centre of Viralogy and Biotechnology

Home - [Website not responding [404 error]

WestVac Biopharma

Media - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.] <u>Website</u> [No News/Announcements page identified]

::::::

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: <u>WHO</u>
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

::::::

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 15, 2023 Issue 3 https://www.tandfonline.com/toc/uabr21/current [Reviewed earlier]

AMA Journal of Ethics

Volume 26, Number 8: E591-664 Auy 2024

https://journalofethics.ama-assn.org/issue/harm-reduction-and-opioid-use-disorder

Standards in Medical-Legal Partnerships

Complex demands of patients' socially, culturally, and politically situated health needs have given rise to what have become known as medical-legal partnerships (MLPs). An MLP is a model of US-based health and legal service provision that generally looks to offer combined, single-site interprofessional responses to patients whose health status and access to health services can be compromised by their need for legal help. Patients who are immigrants, were recently incarcerated, or lack reliable and safe shelter or employment, for example, can experience health vulnerabilities that call for legal expertise, perhaps in the form of advice; aid in petitioning a court or program; referral; representation in administrative proceedings; or advocacy. This theme issue investigates strategies by which clinicians and attorneys should work together to screen for and ably respond with care to legal determinants of patients' health.

American Journal of Human Genetics

Aug 08, 2024 Volume 111 Issue -1796 https://www.cell.com/ajhg/current **This Month in** *The Journal*

Alyson B. Barnes, Kylee L. Spencer

Transcriptomics can routinely identify genes that are overexpressed, have splicing defects, or exhibit aberrant allele-specific expression. Yet, gene misexpression, also known as ectopic expression, has been less well characterized despite its demonstrated importance in some rare diseases, including congenital limb malformations, congenital hyperinsulinism, and monogenic severe childhood obesity... [Reviewed earlier]

American Journal of Infection Control

August 2024 Volume 52 Issue 8 p865-984 http://www.ajicjournal.org/current [Reviewed earlier]

American Journal of Preventive Medicine

August 2024 Volume 67 Issue 2 p175-318

https://www.ajpmonline.org/current

[Reviewed earlier]

American Journal of Public Health

September 2024 114(9) http://ajph.aphapublications.org/toc/ajph/current [Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 111 (2024): Issue 2 (Aug 2024) https://www.ajtmh.org/view/journals/tpmd/111/2/tpmd.111.issue-1.xml [Reviewed earlier]

Annals of Internal Medicine

August 2024 Volume 177, Issue 8 https://www.acpjournals.org/toc/aim/current [New issue; No digest content identified]

Artificial Intelligence – An International Journal

Volume 333 August 2024 https://www.sciencedirect.com/journal/artificial-intelligence/vol/333/suppl/C [Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

http://resource-allocation.biomedcentral.com/ (Accessed 31 Aug 2024) [No new digest content identified]

BMC Health Services Research

http://www.biomedcentral.com/bmchealthservres/content (Accessed 31 Aug 2024)

What happens at two? Immunisation stakeholders' perspectives on factors influencing sub-optimal childhood vaccine uptake for toddlers in regional and remote Western Australia

In Western Australia (WA), children aged 24 months living regionally or remotely (non-urban) have suboptimal vaccine uptake. As there has not yet been a systematic approach to understanding the facilitators an...

Authors: Samantha J. Carlson, Sian Tomkinson, Adam Hannah and Katie Attwell

Citation: *BMC Health Services Research* 2024 24:968 Content type: Research Published on: 22 August 2024

<u>Developing a roadmap to reach and sustain 90% full immunization coverage through a cross-sectoral system strengthening strategy in Bihar, India</u>

Reducing childhood mortality by curtailing the incidence of vaccine preventable diseases is contingent upon a robust and high-performing routine immunization system. According to the available data, the full i...

Authors: Manish Ratna, Sanjay Kumar Singh, Narendra Kumar Sinha, Mandar Kannure, Mehak Bhatia,

Mahesh Kumar Aggarwal, Suresh Kumar Dalpath, Saurabh Sharma and Vama Shah

Citation: *BMC Health Services Research* 2024 24:933 Content type: Research Published on: 14 August 2024

BMC Infectious Diseases

http://www.biomedcentral.com/bmcinfectdis/content

(Accessed 31 Aug 2024)

Monitoring the VDPV2 outbreak in Egypt during 2020–2021 highlights the crucial role of environmental surveillance and boosting immunization in combating Poliovirus

Poliovirus is a highly infectious enterovirus (EV) that primarily affects children and can lead to lifelong paralysis or even death. Vaccine-derived polioviruses (VDPVs) are a great threat since they are deriv...

Authors: Menna R. Shabana, Amira Y. Zaghloul, Tamer H. El Shaarawy, Nooran S. Elleboudy and

Khaled M. Aboshanab

Citation: BMC Infectious Diseases 2024 24:866

Content type: Research Published on: 26 August 2024

Rotavirus infections and their genotype distribution pre- and post-vaccine introduction in Ethiopia: a systemic review and meta-analysis

Rotavirus infections are a significant cause of severe diarrhea and related illness and death in children under five worldwide. Despite the global introduction of vaccinations for rotavirus over a decade ago,

...

Authors: Wagi Tosisa, Belay Tafa Regassa, Daniel Eshetu, Asnake Ararsa Irenso, Andargachew Mulu

and Gadissa Bedada Hundie

Citation: BMC Infectious Diseases 2024 24:836

Content type: Systematic Review Published on: 16 August 2024

BMC Medical Ethics

http://www.biomedcentral.com/bmcmedethics/content

(Accessed 31 Aug 2024)

Opportunities and challenges of a dynamic consent-based application: personalized options for personal health data sharing and utilization

The principles of dynamic consent are based on the idea of safeguarding the autonomy of individuals by providing them with personalized options to choose from regarding the sharing and utilization of personal ...

Authors: Ah Ra Lee, Dongjun Koo, Il Kon Kim, Eunjoo Lee, Sooyoung Yoo and Ho-Young Lee

Citation: *BMC Medical Ethics* 2024 25:92

Content type: Research Published on: 31 August 2024

BMC Medicine

http://www.biomedcentral.com/bmcmed/content

(Accessed 31 Aug 2024)

<u>Influences of HPV disease perceptions, vaccine accessibility, and information exposure on social media on HPV vaccination uptake among 11,678 mothers with daughters aged 9–17 years in China: a cross-sectional study</u>

Mothers play a crucial role in influencing their daughters' HPV vaccination decisions. Addressing barriers to receiving HPV vaccination among mothers of girls may achieve two goals in one strike: increasing va...

Authors: Zian Lin, Siyu Chen, Lixian Su, Yuxue Liao, Hongbiao Chen, Zhiqing Hu, Zhuolin Chen, Yuan

Fang, Xue Liang, Jianan Chen, Biyun Luo, Chuanan Wu and Zixin Wang

Citation: BMC Medicine 2024 22:328

Content type: Research Published on: 13 August 2024

BMC Pregnancy and Childbirth

http://www.biomedcentral.com/bmcpregnancychildbirth/content (Accessed 31 Aug 2024) [No new digest content identified]

BMC Public Health

http://bmcpublichealth.biomedcentral.com/articles

(Accessed 31 Aug 2024)

Behavioral, cognitive and emotional determinants of getting vaccinated for COVID-19 and the mediating role of institutional trust among young adults in Cyprus

Vaccination uptake is a complex behavior, influenced by numerous factors. Behavioral science theories are commonly used to explain the psychosocial determinants of an individual's health behavior. This study e...

Authors: Pinelopi Konstantinou, Maria Kyprianidou, Andria Christodoulou, Louise McHugh, Marios Constantinou, Eleni Epiphaniou, Nigel Vahey, Christiana Nicolaou, Nicos Middleton, Maria Karekla and Angelos P. Kassianos

Citation: BMC Public Health 2024 24:2336

Content type: Research Published on: 28 August 2024

HPV infection and vaccination: a cross-sectional study of knowledge, perception, and attitude to vaccine uptake among university students in Qatar

Human Papilloma Virus (HPV) infection is a significant public health concern in the Gulf Cooperation Council countries, being widely prevalent and the main risk factor for cervical cancer. We aimed to assess k...

Authors: Sohaila Cheema, Amit Abraham, Patrick Maisonneuve, Anupama Jithesh, Karima Chaabna, Reem al Janahi, Shaunak Sarker, Athba Hussain, Shrinidhi Rao, Albert B. Lowenfels and Ravinder Mamtani

Citation: BMC Public Health 2024 24:2316

Content type: Research Published on: 26 August 2024

<u>Public health management of invasive meningococcal disease outbreaks: worldwide 1973–2018, a systematic review</u>

Infectious disease outbreaks are an ongoing public health concern, requiring extensive resources to prevent and manage. Invasive Meningococcal Disease (IMD) is a severe outcome of infection with *Neisseria meningi...*

Authors: Brianna R. Morello, Adriana Milazzo, Helen Siobhan Marshall and Lynne C. Giles

Citation: BMC Public Health 2024 24:2254

Content type: Research Published on: 20 August 2024

<u>Self-reported Infection Status, Knowledge and Associated Factors of Monkeypox Among</u> Men Who Have Sex with Men in Jiaxing, China

As of September 2023, more than 1,000 cases of monkeypox (mpox) have been reported in China. Based on the available evidence, men who have sex with men (MSM) are at high risk for mpox infection. This study aim...

Authors: Yangyang Tian, Zhigang Hou, Guoying Zhu, Qianqian Zhang, Wutong Zhu, Hao Feng, Weizhe

Pan, Qiang Li, Rui Ge and Zhongwen Chen Citation: *BMC Public Health* 2024 24:2250

Content type: Research Published on: 19 August 2024

Attitude towards cholera vaccination and its related factors in Jordan amid the 2022 Middle East outbreak

An outbreak of cholera was reported in the Middle East by the second half of 2022. Raising public awareness and vaccination against cholera represent critical factors in the preventive efforts. The current stu...

Authors: Malik Sallam, Rabaa Y. Athamneh, Rawan Alkhazaleh, Lana Alzayadneh, Laila Jaradat, Tala

Majali, Sarah Obeidat, Aseel Shhab, Souheil Hallit, Muna Barakat and Azmi Mahafzah

Citation: BMC Public Health 2024 24:2237

Content type: Research Published on: 16 August 2024

BMC Research Notes

http://www.biomedcentral.com/bmcresnotes/content (Accessed 31 Aug 2024) [No new digest content identified]

BMJ Evidence-Based Medicine

August 2024 - Volume 29 - 4 https://ebm.bmj.com/content/29/4 [Reviewed earlier]

BMJ Global Health

July 2024 - Volume 9 - 7 https://gh.bmj.com/content/9/7 [Reviewed earlier]

Bulletin of the Atomic Scientists

July 2024 https://thebulletin.org/magazine/2024-07/ [Reviewed earlier]

Bulletin of the World Health Organization

Volume 102(7); 2024 Jul 1 https://www.ncbi.nlm.nih.gov/pmc/issues/467549/ [Reviewed earlier]

Cell

Aug 22, 2024 Volume 187 Issue 17 p4431-4812 https://www.cell.com/cell/current
The wide-reaching power of technology

The *Cell* editorial team

Techniques in light detection and ranging that were originally developed to measure the height of clouds are now used for spacecraft landing, forestry, self-driving vehicles, and archaeology. Oftentimes, the most impactful technologies are those that can be used in many different applications. During the 50th anniversary of *Cell*, we are reflecting on technologies that enable advances in a wide range of fields. These techniques are driving forward our understanding of life, our ability to treat diseases, and our capacity to tackle new challenges.

Child Care, Health and Development

Volume 50, Issue 5 September 2024 https://onlinelibrary.wiley.com/toc/13652214/current [Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 116, Issue 2 Pages: 257-477 August 2024 https://ascpt.onlinelibrary.wiley.com/toc/15326535/current

Issue Focus: Model-Informed Drug Development

Clinical Therapeutics

August 2024 Volume 46 Issue 8 p595-660 http://www.clinicaltherapeutics.com/current Editorial

<u>Artificial Intelligence, Drug Development and Frameworks: An Opportunity to Enhance</u> Understanding

Paul Beninger

Published online: August 05, 2024

p595-596

Reviews

Evolution of Drug Development and Regulatory Affairs: The Demonstrated Power of Artificial Intelligence

Linda Nene, et al.

Published online: July 08, 2024

e6-e14 Open Access

Commentary

Repurposing Drugs to Treat Novel Infections: A Proposal for a Decision-Making Framework for Clinicians

Saroj Jayasinghe

Published online: July 04, 2024

e15-e18

Clinical Trials

Volume 21 Issue 4, August 2024 https://journals.sagepub.com/toc/ctja/21/4 [Reviewed earlier]

Conflict and Health

http://www.conflictandhealth.com/ [Accessed 31 Aug 2024] [No new digest content identified]

Contemporary Clinical Trials

Volume 143 August 2024 https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/143/suppl/C [Reviewed earlier]

The CRISPR Journal

Volume 7, Issue 4 / August 2024 https://www.liebertpub.com/toc/crispr/7/4 EditorialFree

AI and SynBio Meet CRISPR Heralding a New Genome Editing Era

Rodolphe Barrangou

Page:179

Published Online:14 August 2024

https://doi.org/10.1089/crispr.2024.0063

Research Articles

<u>Challenging the Boundaries Between Treatment, Prevention, and Enhancement in Human Genome Editing</u>

Margaret Waltz, et al.

Pages:180–187 Published Online: 8 July 2024 https://doi.org/10.1089/crispr.2024.0021

Abstract

Traditional distinctions between treatment and enhancement goals for human genome editing (HGE) have animated oversight considerations, yet these categories have been complicated by the addition of prevention as a possible target for HGE applications. To assess the role these three categories might play in continued HGE governance efforts, we report on interviews with genome editing scientists and governance group members. While some accepted traditional distinctions between treatment and enhancement and rejected the latter as unacceptable, others argued that the concept of enhancement is largely irrelevant or not as morally problematic as suggested. Others described how preventive goals for HGE create gray zones where prevention and enhancement may be difficult to distinguish, which may stymie uses of HGE. We conclude by discussing the governance implications of these various understandings of treatment, prevention, and enhancement as HGE research moves beyond the treatment of serious disease to embrace longer range preventive goals.

Current Genetic Medicine Reports

Volume 11, Issue 3-4 December 2023 https://link.springer.com/journal/40142/volumes-and-issues/11-3 [Reviewed earlier]

Current Medical Research and Opinion

Volume 40, Issue 8 2024 https://www.tandfonline.com/toc/icmo20/current [Reviewed earlier]

Current Opinion in Infectious Diseases

August 2024 - Volume 37 - Issue 4 https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx [Reviewed earlier]

Current Protocols in Human Genetics

https://currentprotocols.onlinelibrary.wiley.com/journal/19348258 [Accessed 31 Aug 2024] [No new digest content identified]

Developing World Bioethics

Volume 24, Issue 2 Pages: 49-134 June 2024 https://onlinelibrary.wiley.com/toc/14718847/current [Reviewed earlier]

Development in Practice

Volume 34, Issue 4, 2024 https://www.tandfonline.com/toc/cdip20/34/4 [Reviewed earlier]

Development Policy Review

Volume 42, Issue 4 July 2024 https://onlinelibrary.wiley.com/toc/14677679/current [Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 18 - 2024

https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue

[Reviewed earlier]

Disasters

Volume 48, Issue 3 July 2024 https://onlinelibrary.wiley.com/toc/14677717/2024/48/3 [Reviewed earlier]

EMBO Reports

Volume 25 Issue 8 9 August 2024 https://www.embopress.org/toc/14693178/current [Reviewed earlier]

Emerging Infectious Diseases

Volume 30, Number 7—July 2024 http://wwwnc.cdc.gov/eid/ [Reviewed earlier]

Epidemics

Volume 47 June 2024 https://www.sciencedirect.com/journal/epidemics/vol/47/suppl/C [Reviewed earlier]

Epidemiology and Infection

Volume 152 - 2024 https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue [Reviewed earlier]

Ethics & Human Research

Volume 46, Issue 4 Pages: 1-51 July–August 2024
https://onlinelibrary.wiley.com/toc/25782363/current
Research with refugee populations
Ethical considerations for crowdsourced research
[Reviewed earlier]

Ethics & International Affairs

Volume 37 - Issue 4 - Winter 2023 https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue [Reviewed earlier]

Ethics, Medicine and Public Health

Volume 31 (December 2023) https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C [Reviewed earlier]

The European Journal of Public Health

Volume 34, Issue 4, August 2024 https://academic.oup.com/eurpub/issue/34/4 [Reviewed earlier]

Expert Review of Vaccines

Vol 23 (1) 2023 https://www.tandfonline.com/toc/ierv20/current [Reviewed earlier]

Foreign Affairs

July/August 2024 Volume 103, Number 4 https://www.foreignaffairs.com/issues/2023/103/4 [Reviewed earlier]

Forum for Development Studies

Volume 51, 2024 - Issue 2 http://www.tandfonline.com/toc/sfds20/current [Reviewed earlier]

Genetics in Medicines

Volume 26, Issue 8 August 2024 https://www.sciencedirect.com/journal/genetics-in-medicine/vol/26/issue/8 [Reviewed earlier]

Genome Medicine

https://genomemedicine.biomedcentral.com/articles

[Accessed 31 Aug 2024]

Genome Tunisia Project: paving the way for precision medicine in North Africa

Key discoveries and innovations in the field of human genetics have led to the foundation of molecular and personalized medicine. Here, we present the Genome Tunisia Project, a two-phased initiative (2022–2035) w...

Authors: Yosr Hamdi, Mediha Trabelsi, Kais Ghedira, Maroua Boujemaa, Ikhlas Ben Ayed, Cherine Charfeddine, Amal Souissi, Imen Rejeb, Wafa Kammoun Rebai, Chaima Hkimi, Fadoua Neifar, Nouha Jandoubi, Rahma Mkaouar, Melek Chaouch, Ayda Bennour, Selim Kamoun...

Citation: Genome Medicine 2024 16:104

Content type: Research Published on: 27 August 2024

Global Health Action

Volume 17, Issue 1 (2024) https://www.tandfonline.com/toc/zgha20/current?nav=tocList [Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 12, No. 4 August 27, 2024 http://www.ghspjournal.org/content/current COMMENTARIES Open Access

<u>Continuous Community Engagement Is Needed to Improve Adherence to Ebola Response</u> Activities and Survivorship During Ebola Outbreaks

Gnakub Norbert Soke, Peter Fonjungo, Gisele Mbuyi, Richard Luce, John Klena, Mary Choi, John Kombe, Gerry Makaya, Francis Mbuyi, Henriette Bulambo, Mathias Mossoko, Celestin Mwanzembe, Bienvenu Ikomo, Pierre Adikey, Joel Montgomery, Trevor Shoemaker, Placide Mbala, Giulia Earle-Richardson, Dieudonne Mwamba and Jean-Jacques Muyembe Tamfum

Global Health: Science and Practice August 2024, 12(4):e2300006; https://doi.org/10.9745/GHSP-D-23-00006

Engaging communities in Ebola preparedness activities between Ebola outbreaks can not only improve community adherence to response interventions but also potentially help to improve survivorship in these communities during future Ebola outbreaks.

Global Legal Monitor & Legal Reports - Library of Congress/USA

https://www.loc.gov/collections/global-legal-monitor/

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 31 Aug 2024]

[No new digest content identified]

Global Public Health

Volume 19, Issue 1 (2024) http://www.tandfonline.com/toc/rgph20/current [Reviewed earlier]

Globalization and Health

http://www.globalizationandhealth.com/ [Accessed 31 Aug 2024] [No new digest content identified]

Health and Human Rights

Volume 26, Issue 1, June 2024 https://www.hhrjournal.org/volume-26-issue-1-june-2024/ SPECIAL SECTION — COMMEMORATING 30 YEARS [Reviewed earlier]

Health Economics, Policy and Law

Volume 19 - Issue 2 - April 2024 https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue [Reviewed earlier]

Health Policy and Planning

Volume 39, Issue 7, August 2024 https://academic.oup.com/heapol/issue/39/7 [Reviewed earlier]

Health Research Policy and Systems

http://www.health-policy-systems.com/content [Accessed 31 Aug 2024] [No new digest content identified]

Human Gene Therapy

Volume 35, Issue 15-16 / August 2024 https://www.liebertpub.com/toc/hum/35/15-16 Review Articles Free

The Legal Status and Improvement Path of Human Genetic Data in Gene Therapy in China

<u>Jiajv Chen</u> and <u>Wei Li</u>

Pages:520-526

Published Online:31 July 2024

https://doi.org/10.1089/hum.2024.097

Abstract

In the legal context of Chinese law, genetic data are an object of complex rights. At the level of private law, genetic data contain personal information, thus being protected by the Civil Code and the Personal Information Protection Law. At the level of public law, genetic data are important genetic resource that embody both public and national interests, which should also be regulated by public laws such as the Biosecurity Law and the Data Security Law. The recently issued Regulation on the Administration of Human Genetic Resources have refined the approval and record procedure, in order to promote the utilization of genetic data in China. At present, China still lacks sufficient protection for genetic data privacy, and the "informed consent" and "anonymization" system cannot work effectively. On the path of improvement, we should break constraints of individualism and start from the following three levels to strengthen genetic data privacy protection: formulating specialized legislation and leveraging the functions of group organizations and public interest litigation systems.

Open Access

<u>Improving the Assessment of Risk Factors Relevant to Potential Carcinogenicity of Gene</u>
<u>Therapies: A Consensus Article</u>

<u>Jan C. Klapwijk</u>, et al. Pages:527–542

Published Online:25 July 2024

https://doi.org/10.1089/hum.2024.033

Humanitarian Practice Network

https://odihpn.org/ Featured Publications [No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 20 Issue 1, 2024 https://www.tandfonline.com/toc/khvi20/20/1?nav=tocList Selected Content [Reviewed earlier]

Immunity

Jul 09, 2024 Volume 57 Issue 7 p1443-1712 https://www.cell.com/immunity/current [Reviewed earlier]

Infectious Agents and Cancer

http://www.infectagentscancer.com/ [Accessed 31 Aug 2024] [No new digest content identified]

Infectious Diseases of Poverty

http://www.idpjournal.com/content [Accessed 31 Aug 2024]

[No new digest content identified]

International Health

Volume 16, Issue 4, July 2024 https://academic.oup.com/inthealth/issue/16/4 [Reviewed earlier]

International Human Rights Law Review

Volume 13 (2024): Issue 1 (Jun 2024): https://brill.com/view/journals/hrlr/13/1/hrlr.13.issue-1.xml **Special Issue on Inter-State Communications**Table of Contents
[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 11 No. 7 (2024): July 2024 https://www.ijcmph.com/index.php/ijcmph/issue/view/114 [Reviewed earlier]

International Journal of Epidemiology

Volume 53, Issue 3, June 2024 https://academic.oup.com/ije/issue/53/3 [Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 17 Issue 3 2024 https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/3 Table of contents [New issue; No digest content identified]

JAMA

August 27, 2024, Vol 332, No. 8, Pages 603-682 https://jamanetwork.com/journals/jama/currentissue [New issue; No digest content identified]

August 20, 2024, Vol 332, No. 7, Pages 517-600 https://jamanetwork.com/journals/jama/issue/332/7 [New issue; No digest content identified]

August 13, 2024, Vol 332, No. 6, Pages 439-514 https://jamanetwork.com/journals/jama/issue/332/6 [New issue; No digest content identified]

JAMA Health Forum

August 2024, Vol 5, No. 8

https://jamanetwork.com/journals/jama-health-forum/issue [Reviewed earlier]

JAMA Pediatrics

August 2024, Vol 178, No. 8, Pages 735-844 https://jamanetwork.com/journals/jamapediatrics/currentissue [Reviewed earlier]

JBI Evidence Synthesis

July 2024 - Volume 22 - Issue 7 https://journals.lww.com/jbisrir/Pages/currenttoc.aspx [Reviewed earlier]

Journal of Adolescent Health

August 2024 Volume 75 Issue 2 p207-374 https://www.jahonline.org/current [Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 80 (2024) https://www.jair.org/index.php/jair Contents [Reviewed earlier]

Journal of Community Health

Volume 49, Issue 4 August 2024 https://link.springer.com/journal/10900/volumes-and-issues/49-4 [Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 7 No. 01 (2024), January 2, 2024, Page 1988-1996

https://www.cmro.in/index.php/jcmro/issue/view/75
[Reviewed earlier]

Journal of Development Economics

Volume 170 September 2024 https://www.sciencedirect.com/journal/journal-of-development-economics/vol/170/suppl/C [Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 19 Issue 3, July 2024

http://journals.sagepub.com/toc/jre/current

Special Issues in Research and IRB/REC Functioning, Including the use of AI

[Reviewed earlier]

Journal of Epidemiology & Community Health

August 2024 - Volume 78 - 8 https://jech.bmj.com/content/78/8 [New issue; No digest content identified]

Journal of Evidence-Based Medicine

Volume 17, Issue 2 Pages: 237-467 June 2024 https://onlinelibrary.wiley.com/toc/17565391/current [Reviewed earlier]

Journal of Global Ethics

Volume 20, Issue 1 (2024) http://www.tandfonline.com/toc/rjge20/current [Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 35, Number 3, August 2024 https://muse.jhu.edu/issue/52935 Table of Contents [New issue; No digest content identified]

Journal of Immigrant and Minority Health

Volume 26, Issue 4 August 2024 https://link.springer.com/journal/10903/volumes-and-issues/26-4 [New issue; No digest content identified]

Journal of Immigrant & Refugee Studies

Volume 22, 2024 _ Issue 3 https://www.tandfonline.com/toc/wimm20/current [Reviewed earlier]

Journal of International Development

Volume 36, Issue 5 Pages: 3-2503 July 2024 https://onlinelibrary.wiley.com/toc/10991328/current [Reviewed earlier]

Journal of Medical Ethics

September 2024 - Volume 50 - 9 http://jme.bmj.com/content/current [New issue; No digest content identified]

Journal of Patient-Centered Research and Reviews

Volume 11, Issue 1 (2024) https://institutionalrepository.aah.org/jpcrr/ [Reviewed earlier]

The Journal of Pediatrics

Volume 270 July 2024 https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/270/suppl/C [Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

Volume 17, Issue 1 (2024) Issue 1 https://www.tandfonline.com/toc/jppp20/17/1 [Reviewed earlier]

Journal of Public Health Management & Practice

July/August 2024 - Volume 30 - Issue 4 https://journals.lww.com/jphmp/pages/currenttoc.aspx [Reviewed earlier]

Journal of Public Health Policy

Volume 45, issue 3, September 2024 https://link.springer.com/journal/41271/volumes-and-issues/45-3 [Reviewed earlier]

Journal of the Royal Society – Interface

August 2024 Volume 21 Issue 217 https://royalsocietypublishing.org/toc/rsif/current [Reviewed earlier]

Journal of Travel Medicine

Volume 31, Issue 6, August 2024 https://academic.oup.com/jtm/issue [Reviewed earlier]

Journal of Virology

Volume 98 • Number 6 • June 2024 http://jvi.asm.org/content/current [Reviewed earlier]

The Lancet

Aug 31, 2024 Volume 404 Number 10455 p823-906, e3-e4

https://www.thelancet.com/journals/lancet/issue/current

[New issue; No digest content identified]

Aug 24, 2024 Volume 404 Number 10454 p725-822, e1-e2

https://www.thelancet.com/journals/lancet/issue/vol404no10454/PIIS0140-6736(24)X0034-3 *Editorial*

Mpox: the need for a coordinated international response

The Lancet

Comment

The mpox emergency and the role of Gavi

Sania Nishtar, CEO, Gavi

Aug 17, 2024 Volume 404 Number 10453 p629-724

https://www.thelancet.com/journals/lancet/issue/vol404no10453/PIIS0140-6736(24)X0033-1 Review

Long COVID: a clinical update

Trisha Greenhalgh, Manoj Sivan, Alice Perlowski, Janko Ž Nikolich

The Lancet Child & Adolescent Health

Aug 2024 Volume 8 Number 8 p545-610 https://www.thelancet.com/journals/lanchi/issue/current [Reviewed earlier]

Lancet Digital Health

Aug 2024 Volume 6 Number 8 e536-e600 https://www.thelancet.com/journals/landig/issue/current [Reviewed earlier]

Lancet Global Health

Aug 2024 Volume 12 Number 8 e1214-e1369 https://www.thelancet.com/journals/langlo/issue/current [Reviewed earlier]

Lancet Infectious Diseases

Aug 2024 Volume 24 Number 8 p793-934, e473-e539 https://www.thelancet.com/journals/laninf/issue/current [Reviewed earlier]

Lancet Public Health

Aug 2024 Volume 9 Number 8 e533-e634 https://www.thelancet.com/journals/lanpub/issue/current [Reviewed earlier]

Lancet Respiratory Medicine

Aug 2024 Volume 12 Number 8 p575-654, e43-e51

https://www.thelancet.com/journals/lanres/issue/current [Reviewed earlier]

Maternal and Child Health Journal

Volume 28, Issue 7 July 2024 https://link.springer.com/journal/10995/volumes-and-issues/28-7 [Reviewed earlier]

Medical Decision Making (MDM)

Volume 44 Issue 5, July 2024 http://mdm.sagepub.com/content/current [Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy Volume 102, Issue 2 Pages: 271-516 June 2024 https://onlinelibrary.wiley.com/toc/14680009/current [Reviewed earlier]

Molecular Therapy

Aug 07, 2024 Volume 32 Issue 8 p2427-2800 https://www.cell.com/molecular-therapy/current [Reviewed earlier]

Nature

Volume 632 Issue 8027, 29 August 2024 https://www.nature.com/nature/volumes/632/issues/8027. EDITORIAL 27 August 2024

AI firms must play fair when they use academic data in training

Researchers are among those who feel uneasy about the unrestrained use of their intellectual property in training commercial large language models. Firms and regulators need to agree the rules of engagement.

Volume 632 Issue 8026, 22 August 2024 https://www.nature.com/nature/volumes/632/issues/8026 [New issue; No digest content identified]

Volume 632 Issue 8025, 15 August 2024 https://www.nature.com/nature/volumes/632/issues/8025 [New issue; No digest content identified]

Nature Biotechnology

Volume 42 Issue 7, July 2024 https://www.nature.com/nbt/volumes/42/issues/7 [Reviewed earlier]

Nature Communications

https://www.nature.com/subjects/health-sciences/ncomms (Accessed31 Aug 2024) [No new digest content identified]

Nature Genetics

Volume 56 Issue 7, July 2024 https://www.nature.com/ng/volumes/56/issues/7 [Reviewed earlier]

Nature Human Behaviour

Volume 8 Issue 7, July 2024 https://www.nature.com/nathumbehav/volumes/8/issues/7 [Reviewed earlier]

Nature Medicine

Volume 30 Issue 7, July 2024 https://www.nature.com/nm/volumes/30/issues/7 [Reviewed earlier]

Nature Reviews Drug Discovery

Volume 23 Issue 8, August 2024 https://www.nature.com/nrd/volumes/23/issues/8 [Reviewed earlier]

Nature Reviews Genetics

Volume 25 Issue 8, August 2024 https://www.nature.com/nrg/volumes/25/issues/8 [Reviewed earlier]

Nature Reviews Immunology

Volume 24 Issue 8, August 2024 https://www.nature.com/nri/volumes/24/issues/8 [Reviewed earlier]

New England Journal of Medicine

Volume 391 No. 8 August 22/29, 2024 https://www.nejm.org/toc/nejm/medical-journal Perspective

<u>Efforts toward Equity: Academic Medical Center-Public Health Partnerships for Outbreak Response — Collaborating with Underresourced Communities</u>

E. Davis, S. Mayer, and M. Pacilli

<u>Preventing and Controlling Global Antimicrobial Resistance — Implementing a Whole-System Approach</u>

D. Goldmann, S. Rajan, and K. Udayakumar

Volume 391 No. 7 August 15, 2024 https://www.nejm.org/toc/nejm/391/7

Perspective

<u>Fundamentals of Medical Ethics: Medical Expertise — Balancing Science, Values, and Trust</u>

B.H. Lerner

NEJM Evidence

Volume 3 No. 8 August 2024

https://evidence.nejm.org/toc/evid/current

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[Reviewed earlier]

njp Vaccines

https://www.nature.com/npjvaccines/ [Accessed 31 Aug 2024] [No new digest content identified]

Pediatrics

Volume 154, Issue 2 August 2024 https://publications.aap.org/pediatrics/issue/154/2 [Reviewed earlier]

PharmacoEconomics

Volume 42, Issue 7 July 2024 https://link.springer.com/journal/40273/volumes-and-issues/42-7 [Reviewed earlier]

PLoS Biology

https://journals.plos.org/plosbiology/ (Accessed 31 Aug 2024) [No new digest content identified]

PLoS Genetics

https://journals.plos.org/plosgenetics/ (Accessed 31 Aug 2024) [No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&g=&resultsPerPage=60

(Accessed 31 Aug 2024)

The case for a global therapeutics development coalition: Building a therapeutics pipeline for pandemic and endemic diseases

Shingai Machingaidze, Carmen Pérez Casas, Sheila Mburu, Ruxandra Draghia-Akli, Charles Mowbray, James Rosen, Esteban Burrone, Mona Nemer, Victor Dzau

Opinion | published 30 Aug 2024 PLOS Global Public Health

https://doi.org/10.1371/journal.pgph.0003654

The case for a global therapeutics development coalition: Building a therapeutics pipeline for pandemic and endemic diseases

Shingai Machingaidze, Carmen Pérez Casas, Sheila Mburu, Ruxandra Draghia-Akli, Charles Mowbray, James Rosen, Esteban Burrone, Mona Nemer, Victor Dzau

Opinion | published 30 Aug 2024 PLOS Global Public Health

https://doi.org/10.1371/journal.pgph.0003654

The case for a global therapeutics development coalition: Building a therapeutics pipeline for pandemic and endemic diseases

Shingai Machingaidze, Carmen Pérez Casas, Sheila Mburu, Ruxandra Draghia-Akli, Charles Mowbray, James Rosen, Esteban Burrone, Mona Nemer, Victor Dzau

Opinion | published 30 Aug 2024 PLOS Global Public Health

https://doi.org/10.1371/journal.pgph.0003654

PLoS Medicine

http://www.plosmedicine.org/ (Accessed 31 Aug 2024) [Website not responding at inquiry]

PLoS Neglected Tropical Diseases

http://www.plosntds.org/ (Accessed 31 Aug 2024)

Role of the dengue vaccine TAK-003 in an outbreak response: Modeling the Sri Lanka experience

LakKumar Fernando, Randee Kastner, Pujitha Wickramasinghe, Asvini D. Fernando, Dulanie Gunasekera, Van Hung Nguyen, Mengya Liu, Inge LeFevre, Derek Wallace, Nicolas Folschweiller, Shibadas Biswal

Research Article | published 22 Aug 2024 PLOS Neglected Tropical Diseases https://doi.org/10.1371/journal.pntd.0012376

PLoS One

http://www.plosone.org/ [Accessed 31 Aug 2024]

COVID-19 vaccination intention among internally displaced persons in complex humanitarian emergency context, Northeast Nigeria

Saheed Gidado, Melton Musa, Ahmed Ibrahim Ba'aba, Lilian Akudo Okeke, Patrick M. Nguku, Isa Ali Hassan, Ibrahim Muhammad Bande, Rabi Usman, Gideon Ugbenyo, Idris Suleman Hadejia, J. Pekka Nuorti, Salla Atkins

Research Article | published 30 Aug 2024 PLOS ONE

https://doi.org/10.1371/journal.pone.0308139

Religious beliefs and practices toward HPV vaccine acceptance in Islamic countries: A scoping review

Sezer Kisa, Adnan Kisa

Research Article | published 29 Aug 2024 PLOS ONE

https://doi.org/10.1371/journal.pone.0309597

Vaccine practices, literacy, and hesitancy among parents in the United Arab Emirates

Hiba Jawdat Barqawi, Kamel A. Samara, Samah Mohamed Kannas, Omar Habbal, Nada A. AlSarraf, Mohammad A. Dreezi, Eman Abu-Gharbieh

Research Article | published 27 Aug 2024 PLOS ONE

https://doi.org/10.1371/journal.pone.0307020

Evaluating research ethics committees in Vietnam and Laos: Results of a validated self-assessment tool

Nathan Gabriel Sattah, Vincent D'Anniballe, Hoang Tu Le, Luyen Thi Le, Thanh Ngoc Le, Thom Thi Vu, Viengsakhone Louangpradith, Walter T. Lee

Research Article | published 22 Aug 2024 PLOS ONE

https://doi.org/10.1371/journal.pone.0309084

PLoS Pathogens

http://journals.plos.org/plospathoge ns/ [Accessed 31 Aug 2024] [No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

August 27, 2024 vol. 121 no. 35

https://www.pnas.org/toc/pnas/121/35

Research Article August 20, 2024

<u>ChatGPT as Research Scientist: Probing GPT's capabilities as a Research Librarian, Research Ethicist, Data Generator, and Data Predictor</u>

How good a research scientist is ChatGPT? We systematically probed the capabilities of GPT-3.5 and GPT-4 across four central components of the scientific process: as a Research Librarian, Research Ethicist, Data Generator, and Novel Data Predictor, using ...

Steven A. Lehr, Aylin Caliskan, [...] Mahzarin R. Banaji

August 20, 2024 | vol. 121 | no. 34

https://www.pnas.org/toc/pnas/121/34

Perspective August 14, 2024

The path to scientifically sound biodiversity valuation in the context of the Global Biodiversity Framework

Successful implementation of the Kunming-Montreal Global Biodiversity Framework requires identifying a process for measuring and valuing changes in biodiversity that build on the recognition that economics and valuation must play a key role in "halting ...

Eli P. Fenichel, Monica F. Dean and Oswald J. Schmitz

Research Article August 14, 2024

<u>Vulnerability in research ethics: A call for assessing vulnerability and implementing protections</u>

Ethics standards reference the need for special consideration of vulnerable populations, such as pregnant women, incarcerated individuals, and minors. The concept of vulnerability is poorly conceptualized in the medical sciences where it originated, and ...

Michael G. Findley, Faten Ghosn and Sara J. Lowe

August 13, 2024 | vol. 121 | no. 33 https://www.pnas.org/toc/pnas/121/33 [New issue; No digest content identified]

PNAS Nexus

Volume 3, Issue 7, July 2024 https://academic.oup.com/pnasnexus/issue/3/7 [Reviewed earlier]

Prehospital & Disaster Medicine

Volume 39 - Issue 2 - April 2024 https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue [Reviewed earlier]

Preventive Medicine

Volume 184 July 2024 https://www.sciencedirect.com/journal/preventive-medicine/vol/184/suppl/C [Reviewed earlier]

Proceedings of the Royal Society B

August 2024 Volume 291 Issue 2028 https://royalsocietypublishing.org/toc/rspb/current [Reviewed earlier]

Public Health

Volume 232 Pages 1-208 (July 2024) https://www.sciencedirect.com/journal/public-health/vol/232/suppl/C [Reviewed earlier]

Public Health Ethics

Volume 17, Issue 1-2, April/July 2024 http://phe.oxfordjournals.org/content/current [Reviewed earlier]

Public Health Genomics

2024, Vol. 27, No. 1 https://karger.com/phg/issue/27/1 [Reviewed earlier]

Public Health Reports

Volume 139 Issue 4, July/August 2024 https://journals.sagepub.com/toc/phrg/139/4 [Reviewed earlier]

Qualitative Health Research

Volume 34 Issue 7, June 2024 https://journals.sagepub.com/toc/QHR/current [Reviewed earlier]

Research Ethics

Volume 20 Issue 3, July 2024 http://journals.sagepub.com/toc/reab/current [Reviewed earlier]

Reproductive Health

http://www.reproductive-health-journal.com/content [Accessed 31 Aug 2024] [No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

https://www.paho.org/journal/en Latest Articles 27 Aug 2024

The scope and sustainability of, and data about, utilization of embedded research: qualitative evidence from Latin America and the Caribbean

Original research | English |

19 Aug 2024

<u>Improving spatial accessibility to health care services in Cali, Colombia: stakeholder assessment of an innovative platform</u>

Original research | English |

13 Aug 2024

<u>High-cost medicines: the difficult balance between individual and collective rights</u>
Opinion and analysis | Spanish |

13 Aug 2024

<u>Social participation in health: analysis of progress and challenges for the Region of the Americas</u>

Opinion and analysis | English |

Risk Analysis

Volume 44, Issue 7 Pages: 1535-172 July 2024 https://onlinelibrary.wiley.com/toc/15396924/current [Reviewed earlier]

Risk Management and Healthcare Policy

https://www.dovepress.com/risk-management-and-healthcare-policy-archive56 [Accessed 31 Aug 2024] [Reviewed earlier]

Science

Volume 385| Issue 6712| 30 Aug 2024 https://www.science.org/toc/science/current

Editorial

Protect the safety of researchers

BY Janneke Gerards 29 Aug 2024: 9

Volume 385| Issue 6711| 23 Aug 2024 https://www.science.org/toc/science/385/6711 Policy Forum

AI and biosecurity: The need for governance

BY Doni Bloomfield, et al. 22 Aug 2024: 831-833

Governments should evaluate advanced models and if needed impose safety measures

Reviews

The value of decentralized clinical trials: Inclusion, accessibility, and innovation

BY Girardin Jean-Louis, Azizi A. Seixas

23 Aug 2024

Volume 385| Issue 6710| 16 Aug 2024

https://www.science.org/toc/science/385/6710

Expert Voices

The Turing Test and our shifting conceptions of intelligence

BY Melanie Mitchell 15 Aug 2024

Science and Engineering Ethics

Volume 30, Issue 4 August 2024 https://link.springer.com/journal/11948/volumes -and-issues/30-4 [Reviewed earlier]

Science Translational Medicine

Volume 16| Issue 762| 28 Aug 2024 https://www.science.org/toc/stm/current [New issue; No digest content identified]

Volume 16| Issue 761| 21 Aug 2024 https://www.science.org/toc/stm/16/761 [New issue; No digest content identified] Volume 16| Issue 760| 14 Aug 2024 https://www.science.org/toc/stm/16/760 [New issue; No digest content identified]

Volume 16| Issue 759| 7 Aug 2024 https://www.science.org/toc/stm/16/759 [New issue; No digest content identified]

Scientific Reports

https://www.nature.com/srep/articles?type=article [Accessed 31 Aug 2024] [No new digest content identified]

Social Science & Medicine

Volume 350 June 2024 https://www.sciencedirect.com/journal/social-science-and-medicine/vol/350/suppl/C [Reviewed earlier]

Systematic Reviews

https://systematicreviewsjournal.biomedcentral.com/articles [Accessed 31 Aug 2024] [No new digest content identified]

Theoretical Medicine and Bioethics

Volume 45, Issue 4 August 2024 https://link.springer.com/journal/11017/volumes-and-issues/45-4 [Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 60 July–August 2024 https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/60/suppl/C [Reviewed earlier]

Tropical Medicine & International Health

Volume 29, Issue 8 Pages: i-iv, 657-755 August 2024 https://onlinelibrary.wiley.com/toc/13653156/current [Reviewed earlier]

Vaccine

Volume 42, Issue 21 30 August 2024 https://www.sciencedirect.com/journal/vaccine/vol/42/issue/21 Selected Content Review article Abstract only

<u>Timing of pertussis vaccination during pregnancy: Evidence and implementation – A systematic review</u>

Louise De Weerdt, Sereina A. Herzog, Pierre Van Damme, Kirsten Maertens Article 126152

Research article Abstract only

<u>Safety and 6-month immune persistence of inactivated poliovirus vaccine (Sabin strains)</u> <u>simultaneously administrated with other vaccines for primary and booster immunization in Jiangxi Province, China</u>

Shicheng Guo, Zhen Li, Min Zheng, Fengyun Wu, ... Dan Yu Article 126183

Research article Open access

The life cycle of vaccines evaluated by the European Medicines Agency

Débora D. Gräf, Lukas Westphal, Christine E. Hallgreen Article 126186

Research article Abstract only

<u>Assessing real world vaccine effectiveness: A review of Scotland's approach to monitoring human papillomavirus (HPV) vaccine impact on HPV infection and cervical disease</u>

Ross L Cameron, Tim J Palmer, Kate Cuschieri, Kimberley Kavanagh, Kirsty Roy Article 126177

Research article Abstract only

Assessing real world vaccine effectiveness: A review of Scotland's approach to monitoring human papillomavirus (HPV) vaccine impact on HPV infection and cervical disease

Ross L Cameron, Tim J Palmer, Kate Cuschieri, Kimberley Kavanagh, Kirsty Roy Article 126177

Research article Abstract only

Assessing real world vaccine effectiveness: A review of Scotland's approach to monitoring human papillomavirus (HPV) vaccine impact on HPV infection and cervical disease

Ross L Cameron, Tim J Palmer, Kate Cuschieri, Kimberley Kavanagh, Kirsty Roy Article 126177

Research article Open access

COVID-19 vaccination reluctance across Europe: Lessons for the future

Abdul Suleman, Paula Vicente Article 126168

Vaccines

https://www.mdpi.com/journal/vaccines

[Accessed 31 Aug 2024]

Open Access Article

<u>Indonesian Mothers' Experience of Their Daughter's HPV Vaccination, and Factors</u>

Associated with Their Willingness to Recommend HPV Vaccination for Girls

by Setiyani Marta Dewi, Ariane Juliana Utomo, Linda Rae Bennett, Siswanto Agus Wilopo and Anna Barrett

Vaccines 2024, 12(9), 998; https://doi.org/10.3390/vaccines12090998 - 30 Aug 2024 Abstract

In Indonesia, knowledge of parents' experiences of their daughters' HPV vaccination in school settings is limited. As Indonesia seeks to scale up its HPV vaccination program nationwide, parents'

perspectives hold important insights into how elements of the vaccination model can be sustained and [...]

Value in Health

August 2024 Volume 27 Issue 8 p999-1174 https://www.valueinhealthjournal.com/current [Reviewed earlier]

World Development

Volume 180 August 2024 https://www.sciencedirect.com/journal/world-development/vol/180/suppl/C [Reviewed earlier]

::::::

Contents [click to move among sections]

:: Milestones, Perspectives

:: <u>WHO</u>

:: Organization Announcements

:: Journal Watch

:: Pre-Print Servers

::::::

Pre-Print Servers

arxiv

https://arxiv.org/

[Accessed 31 Aug 2024]

[Filter: Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics]

arXiv:2401.13023 (replaced) [pdf, other]

Enabling Global Image Data Sharing in the Life Sciences

Peter Bajcsy, Sreenivas Bhattiprolu, Katy Boerner, Beth A Cimini, Lucy Collinson, Jan Ellenberg, Reto Fiolka, Maryellen Giger, Wojtek Goscinski, Matthew Hartley, Nathan Hotaling, Rick Horwitz, Florian Jug, Anna Kreshuk, Emma Lundberg, Aastha Mathur, Kedar Narayan, Shuichi Onami, Anne L. Plant, Fred Prior, Jason Swedlow, Adam Taylor, Antje Keppler

Comments: This manuscript (arXiv:2401.13023) is published with a closely related companion entitled, Harmonizing the Generation and Pre-publication Stewardship of FAIR Image Data, which can be found at the following link, arXiv:2401.13022

Subjects: Other Quantitative Biology (q-bio.OT)

Coordinated collaboration is essential to realize the added value of and infrastructure requirements for global image data sharing in the life sciences. In this White Paper, we take a first step at presenting some of the most common use cases as well as critical/emerging use cases of (including the use of artificial intelligence for) biological and medical image data, which would benefit tremendously from better frameworks for sharing (including technical, resourcing, legal, and ethical aspects). In the second half of this paper, we paint an ideal world scenario for how global image data sharing could work and benefit all life sciences and beyond. As this is still a long way off, we conclude by suggesting several concrete measures directed toward our institutions, existing imaging communities and data

initiatives, and national funders, as well as publishers. Our vision is that within the next ten years, most researchers in the world will be able to make their datasets openly available and use quality image data of interest to them for their research and benefit. This paper is published in parallel with a companion White Paper entitled Harmonizing the Generation and Pre-publication Stewardship of FAIR Image Data, which addresses challenges and opportunities related to producing well-documented and high-quality image data that is ready to be shared. The driving goal is to address remaining challenges and democratize access to everyday practices and tools for a spectrum of biomedical researchers, regardless of their expertise, access to resources, and geographical location.

Gates Open Research

https://gatesopenresearch.org/browse/articles

[Accessed 31 Aug 2024]

Study Protocol metrics AWAITING PEER REVIEW

<u>Vaccine decision-making among pregnant women: a protocol for a cross-sectional mixed-method study in Brazil, Ghana, Kenya and Pakistan</u>

[version 1; peer review: awaiting peer review]

Jessica L Schue, Prachi Singh, Berhaun Fesshaye, Emily S Miller, Shanelle Quinn, Ruth A Karron, Renato T Souza, Maria Laura Costa, Jose Guilherme Cecatti, Kwasi Torpey, Caroline Dinam Badzi, Emefa Modey, Chris Guure, Ferdinand Okwaro, Marleen Temmerman, Saleem Jessani, Sarah Saleem, Muhammad Asim, Sidrah Nausheen, Haleema Yasmeen, Grace Belayneh, Vanessa Brizuela, Sami Gottlieb, Rupali J Limaye

Peer Reviewers Invited

Funder

UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), a cosponsored programme executed by the World Health Organization (WHO).

PUBLISHED 29 Aug 2024

Study Protocol metrics AWAITING PEER REVIEW

Enhancing maternal health service utilization among highly vulnerable pregnant women through a human-centered design process: Study protocol for a quasi-experimental study in Oromia, Ethiopia

[version 1; peer review: awaiting peer review]

Bee-Ah Kang, Habtamu Tamene, Yihunie Lakew, Daryl Stephens, Rajiv Rimal

Peer Reviewers Invited

Funder

The Bill and Melinda Gates Foundation

PUBLISHED 27 Aug 2024

medRxiv

https://www.medrxiv.org/content/about-medrxiv

[Accessed 31 Aug 2024] [Filter: All articles]

<u>Trends of drug use with suggested shortages and their alternatives across 41 real world data sources and 18 countries in Europe and North America</u>

Marta Pineda-Moncus

doi: https://doi.org/10.1101/2024.08.28.24312695

Main outcomes and measures We estimated annual incidence rates and period prevalence of all medicines with suggested shortages and their alternatives. A drop in incidence or prevalence of more

than 33% after the shortage announce by the European Medicines Agency was considered confirmation of a shortage.

Results Among 41 databases from Europe and the United States, we observed shortages according to incidence for 12 drugs and shortages according to prevalence for 4 drugs. The drugs varenicline, cetrorelix, and amoxicillin plus clavulanate were in shortage in the most countries.

Conclusion and relevance We compiled and analysed data of annual incidence and prevalence of 57 medicines among 41 databases in Europe and the United States. We detected shortages of several drugs and suggest monitoring and stewardship for drug availability.

A systematic review and modelling insights of factors impacting measles vaccine effectiveness

Samiran Ghosh, Divya Kappara, Nabanita Majumder, Suchita Nath-Sain, Siuli Mukhopadhyay medRxiv 2024.08.29.24312705; doi: https://doi.org/10.1101/2024.08.29.24312705

An equity-focused comparison of the COVID-19 vaccine rollout plans across six Canadian provinces

Mercedes Sobers, Vajini Atukorale, Dane Mauer-Vakil, Kainat Bashir, Mariame Ouedraogo, Christoffer Dharma, Anushka Ataullahjan, Shaza A. Fadel, Sara Allin medRxiv 2024.08.28.24312721; doi: https://doi.org/10.1101/2024.08.28.24312721

Monkeypox in Europe: Epidemiology, Risk Factors and Implications for Public Health Actions – A Scoping Review Study

Nandakumar Ravichandran

medRxiv 2024.08.28.24312706; doi: https://doi.org/10.1101/2024.08.28.24312706

Cost-benefit of Influenza Vaccinations in Frontline Workers: A Dynamic Modelling Study

Peter Mortensen, William Gilks, Selina Kim, Richard Bennett, Matthew Linley medRxiv 2024.08.27.24312639; doi: https://doi.org/10.1101/2024.08.27.24312639

Future Pandemics: AI-Designed Assays for Detecting Mpox, General and Clade 1b Specific

Lucero Mendoza-Maldonado, John MacSharry, Johan Garssen, Aletta D. Kraneveld, Alberto Tonda, Alejandro Lopez-Rincon

medRxiv 2024.08.22.24312441; doi: https://doi.org/10.1101/2024.08.22.24312441

<u>Use of large language models as a scalable approach to understanding public health discourse</u>

Laura Espinosa, Marcel Salathé

medRxiv 2024.02.06.24302383; doi: https://doi.org/10.1101/2024.02.06.24302383 Revision
Online public health discourse is becoming more and more important in shaping public health
dynamics. Large Language Models (LLMs) offer a scalable solution for analysing the vast amounts of
unstructured text found on online platforms. Here, we explore the effectiveness of Large Language
Models (LLMs), including GPT models and open-source alternatives, for extracting public stances
towards vaccination from social media posts. Using an expert-annotated dataset of social media posts
related to vaccination, we applied various LLMs and a rule-based sentiment analysis tool to classify the
stance towards vaccination. We assessed the accuracy of these methods through comparisons with
expert annotations and annotations obtained through crowdsourcing. Our results demonstrate that
few-shot prompting of best-in-class LLMs are the best performing methods, and that all alternatives
have significant risks of substantial misclassification...

<u>Clade I Mpox virus genomic diversity in the Democratic Republic of the Congo, 2018 - 2024: Predominance of Zoonotic Transmission</u>

Eddy Kinganda-Lusamaki, Adrienne Amuri-Aziza, Nicolas Fernandez, Jean-Claude Makangara-Cigolo, Catherine Pratt, Emmanuel Hasivirwe Vakaniaki, Nicole A. Hoff, Gradi Luakanda, Prince Akil-Bandali, Sabin Sabiti Nundu, Noella Mulopo-Mukanya, Michel Ngimba, Brigitte Modadra-Madakpa, Ruth Diavita, Princesse Paku, Elisabeth Pukuta-Simbu, Sydney Merritt, Áine O'Toole, Nicola Low, Antoine Nkuba-Ndaye, Hugo Kavunga-Membo, Robert Shongo, Laurens Liesenborghs, Tony Wawina-Bokalanga, Koen Vercauteren, Daniel Mukadi-Bamuleka, Lorenzo Subissi, Jean-Jacques Muyembe, Jason Kindrachuk, Ahidjo Ayouba, Andrew Rambaut, Eric Delaporte, Sofonias Tessema, Eric D'Ortenzio, Anne W. Rimoin, Lisa E. Hensley, Placide Mbala-Kingebeni, Martine Peeters, Steve Ahuka-Mundeke medRxiv 2024.08.13.24311951; doi: https://doi.org/10.1101/2024.08.13.24311951 Revision

<u>Climate Risks to Water, Sanitation and Hygiene Services and Evidence of Inclusive and Effective Interventions in Low and Middle-Income Countries: A Scoping Review</u>

Jane Wilbur, Doug Ruuska, Shahpara Nawaz, Julian Natukunda medRxiv 2024.08.21.24312122; doi: https://doi.org/10.1101/2024.08.21.24312122

Cost-Effectiveness of Vaccination Strategies to Control Future Mpox Outbreaks in England

Xu-Sheng Zhang, Siwaporn Niyomsri, Sema Mandal, Hamish Mohammed, Miranda Mindlin, Bennet Dugbazah, Solomon Adjei, Andre Charlett, Jessica Edney, Elliot Sugars, Merav Kliner, Trish Mannes, Ellie Jewitt, Lorna Gilbert, Samihah Moazam, Claire Dewsnap, David Phillips, Gayatri Amirthalingam, Mary E. Ramsay, Peter Vickerman, Josephine Walker

medRxiv 2024.08.20.24312301; doi: https://doi.org/10.1101/2024.08.20.24312301

<u>Risk Factors of Human Mpox (Monkeypox) Infection: A Systematic Review and Meta-Analysis</u>

Chigozie Louisa J. Ugwu, Nicola Luigi Bragazzi, Jianhong Wu, Jude Dzevela Kong, Ali Asgary, James Orbinski, Woldegebriel Assefa Woldegerima

medRxiv 2024.08.14.24311975; doi: https://doi.org/10.1101/2024.08.14.24311975

Acceptance of an Mpox Vaccine in the Democratic Republic of the Congo: Results from a Nationwide Phone Survey

Skylar Petrichko, Jason Kindrachuk, Dalau Nkamba, Sydney Merritt, Handdy Kalengi, Leonard Kamba, Michael Beya, Megan Halbrook, Nicole A. Hoff, Christophe Luhata, Didine K. Kaba, Anne W. Rimoin medRxiv 2024.08.15.24311971; doi: https://doi.org/10.1101/2024.08.15.24311971 Revision

Global genomic surveillance of monkeypox virus

James R. Otieno, Christopher Ruis, Bernard A. Onoja, Krutika Kuppalli, Ana Hoxha, Andreas Nitsche, Annika Brinkmann, Janine Michel, Placide Mbala-Kisengeni, Daniel Mukadi-Bamuleka, Muntasir Mohammed Osman, Hanadi Elawad Hussein, Muhammad Ali Raja, Richard Fotsing, Belinda L. Herring, Mory Keita, Jairo Mendez Rico, Lionel Gresh, Amal Barakat, Victoria Katawera, Karen Nahapetyan, Dhamari Naidoo, R. Andres Floto, Jane Cunningham, Maria D. Van Kerkhove, Rosamund Lewis, Lorenzo Subissi

medRxiv 2024.08.15.24312031; doi: https://doi.org/10.1101/2024.08.15.24312031

<u>Estimating time-varying cholera transmission and oral cholera vaccine effectiveness in Haiti and Cameroon, 2021-2023</u>

Erin N. Hulland, Marie-Laure Charpignon, Ghinwa Y. El Hayek, Lihong Zhao, Angel N. Desai, Maimuna S. Majumder

medRxiv 2024.06.12.24308792; doi: https://doi.org/10.1101/2024.06.12.24308792 Revision

Efficacy, public health impact and optimal use of the Takeda dengue vaccine

Bethan Cracknell Daniels, Neil Ferguson, Ilaria Dorigatti

medRxiv 2024.08.10.24311393; doi: https://doi.org/10.1101/2024.08.10.24311393

OSF Pre-prints

https://osf.io/preprints/discover?provider=OSF&subject=bepress%7 CLife%20Sciences

[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-Integrating mRNA Vaccines into the Attitudes Toward Genomics and Precision Medicine Scale: A Validation Study with a Sample of 4,939 Adults in the US

<u>Kari Baldwin</u>, <u>Jenine Harris</u>, <u>Erin Solomon</u>, <u>Lauren Baker</u>, <u>Eu Gene Chin</u>, and 1 more

Preprint Date created: 2024-08-20 Date modified: 2024-08-27

Abstract

The Attitudes toward Genomics and Precision Medicine (AGPM) measure examines attitudes toward activities such as genetic testing, gene editing, and biobanking. This is a useful tool for research on the Ethical, Legal, and Social Implications (ELSI) of genomics, a major program within the National Institutes of Health. We updated the AGPM to explore controversies over mRNA vaccines. This Brief Report examines the factor structure of the updated AGPM using a sample of 4,939 adults in the US. The updated AGPM's seven factors include health benefits, knowledge benefits, and concerns about sacredness of life, privacy, gene editing, mRNA vaccines, and social justice.

Wellcome Open Research

https://wellcomeopenresearch.org/browse/articles

[Accessed 31 Aug 2024]

Selected Research

Study Protocol Open Access

REVISED - <u>Understanding the epidemiology of iNTS disease in Africa in preparation for future iNTS- vaccine studies in endemic countries: Seroepidemiology in Africa of iNTS (SAiNTS) Study Protocol: Malawi site [Version 9.0]</u>

[version 2; peer review: 2 approved, 3 approved with reservations]

Helen Dale, et al.

Non-typhoidal Salmonella (NTS) are a major cause of bloodstream infections amongst children in sub-Saharan Africa. A clear understanding of the seroepidemiology and correlates of protection for invasive NTS (iNTS) in relation to key risk factors (malaria, anaemia, malnutrition) in children in Africa is needed to inform strategies for disease control including vaccine implementation

Study Protocol Open Access

The impact of acellular pertussis vaccination in pregnancy on the immunogenicity of acellular versus whole-cell pertusnnsis vaccines in infancy: A protocol for a phase IV randomised, controlled mother-infant pertussis vaccine trial (The Gambian Pertussis Study, GaPs)

[version 1; peer review: awaiting peer review]

Anja Saso, et al.

Worldwide we have yet to achieve optimal control of pertussis, an important vaccine-preventable respiratory disease that has a particularly high burden of morbidity and mortality in infants under 1 year. Pertussis immunisation in pregnancy is an effective tool to protect infants in early life. However, there are concerns regarding the impact of maternal antibodies on the infant's subsequent vaccine responses. The exact nature, duration, and clinical significance of this interaction is poorly understood.

* * * *

Brookings [to 31 Aug 2024]

http://www.brookings.edu/

Research

<u>Sustainable Development Goals - An Interview with Homi Kharas on the Sustainable Development Goals (SDGs) and the UN Summit of the Future</u>

Homi Kharas

August 14, 2024

Center for Global Development [to 31 Aug 2024]

https://www.cgd ev.org/

All Research

WORKING PAPERS

The Cost-Effectiveness of Health Aid: An Exploratory Quantitative Analysis

Victoria Fan et al.

August 26, 2024

One approach to development assistance for health, or health aid, emphasizes the ex ante selection of cost-effective health interventions, an approach that began with the World Development Report (1993) on Investing in Health and has since been adopted by the Effective Altruism community. But just h...

POLICY PAPERS

<u>Financing the Pandemic Cycle: Prevention, Preparedness, Response, and Recovery and Reconstruction</u>

Victoria Fan et al.

August 21, 2024

COVID-19 exposed critical gaps in the global response to health crises, particularly in the financing of pandemic preparedness, response, recovery, and reconstruction. This paper presents a comprehensive framework for pandemic financing that spans the entire pandemic cycle, emphasizing the need for ...

CGD NOTES

Building Institutions for Priority-Setting in Health

Victoria Fan et al.

August 20, 2024

In the pursuit of universal health coverage, countries are invariably confronted with questions about which services to pay with public funds, to whom, and at what cost. Such priority setting processes have major ramifications for the costs and benefit of care delivered. These processes are not just...

Chatham House [to 31 Aug 2024]

https://www.chathamhouse.org/

Selected Analysis, Comment, Events

Expert comment

The global response to the mpox outbreak in Africa will show if lessons from COVID-19 have been learned

The declaration of the rapidly spreading mpox outbreak in Africa as a public health emergency will test global solidarity in the wake of COVID-19 – and could provide a litmus test for the effectiveness of a future pandemic treaty.

15 August 2024

https://www.cfr.org/media/news-releases

New Releases [Selected]

No new digest content identified.

CSIS [to 31 Aug 2024]

https://www.csis.org/

Reports [Selected]

Understanding the U.S. Biopharmaceutical Innovation Ecosystem

While the commercial and national security competition with China has brought policy attention to securing the semiconductor industry, the importance of sustaining a world-leading U.S. biopharmaceutical industry remains underappreciated.

Report by Sujai Shivakumar, Tisyaketu Sirkar, and Jeffrey Depp — August 15, 2024

Kaiser Family Foundation [to 31 Aug 2024]

https://www.kff.org/search/?post_type=press-release

Newsroom

<u>Poll: Most Who Use Artificial Intelligence Doubt AI Chatbots Provide Accurate Health</u> Information

August 15, 2024 News Release

Amid rising interest in and use of artificial intelligence (AI) by individuals and businesses, most of the public (63%), including most AI users (56%), are not confident that AI chatbots provide accurate health information, a new KFF Health Misinformation Tracking Poll finds. The poll comes as AI chatbots such as...

McKinsey Global Institute [to 31 Aug 2024]

https://www.mckinsey.com/mgi/overview

Latest Research

No new digest content identified.

ODI [Overseas Development Institute] [to 31 Aug 2024]

https://odi.org/en/publications/

Publications [Selected]

No new digest content identified.

Pew Research Center [to 31 Aug 2024]

https://www.pewresearch.org/ Latest Publications [Selected] No new digest content identified.

Rand [to 31 Aug 2024]

https://www.rand.org/pubs.html Published Research [Selected]

<u>Patient Safety and the COVID-19 Pandemic: A Qualitative Study of Perspectives of Front-</u> Line Clinicians

Aug 26, 2024

We interviewed clinicians from 16 US hospitals who worked during the COVID-19 pandemic. We identified two primary themes related to patient safety: (1) compromised access to healthcare and (2) impaired care delivery.

The New Bioweapons: How Synthetic Biology Could Destabilize the World

Aug 26, 2024

In olden days, biological weapons were evil and awful. Now, the 21st century ability to design, build, and evolve new contagious pathogens threatens to kill us all. The rise of AI makes this threat yet more threatening. We hope to muddle through.

<u>Centering Equity in the Implementation of Emerging Digital Health Technologies</u> Aug 15, 2024

This paper centers health equity in the implementation of digital health technologies, such as personalized genomic medicine, by adapting methodological frameworks to support planning and evaluation.

Urban Institute [to 31 Aug 2024] https://www.urban.org/publications **New Research Publications - Selected**

World Economic Forum [to 31 Aug 2024]

https://agenda.weforum.org/press/
Media [Selected]
No new digest content identified.

::::::

Public Consultations/Call for Inputs/Call for Papers

<u>Call for Public Comment: General Principles on Plan, Design, and Analysis of Pharmacoepidemiological Studies that Utilize Real-World Data for Safety Assessment of Medicines.</u>

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use]

The guideline will focus on non-interventional pharmacoepidemiological studies using Real-World Data (RWD) and will include basic principles that may apply to these studies when real-world data elements are included.

Public consultation dates [announced to date]:

ANVISA, Brazil - Deadline for comments by 24 August 2024 FDA, United States - Deadline for comments by 3 September 2024 MFDS, Republic of Korea - Deadline for comments by 15 July 2024 MHLW/PMDA, Japan - Deadline for comments by 28 July 2024 NMPA, China - Deadline for comments by 12 October 2024 TFDA, Chinese Taipei - Deadline for comments by 30 September 2024

<u>Vaccines and Related Biological Products Advisory Committee; Notice of Meeting;</u> Establishment of a Public Docket; Request for Comments A Notice by the Food and Drug Administration on 08/20/2024 Comments received **on or before September 12, 2024,** will be provided to the committee.

[Pertussis controlled human infection models (CHIMs)]

The meeting will be held virtually on September 20, 2024, from 8:30 a.m. to 5 p.m. Eastern Time. SUMMARY:

The Food and Drug Administration (FDA or we) announces a forthcoming public advisory committee meeting of the Vaccines and Related Biological Products Advisory Committee (the committee). The general function of the committee is to provide advice and recommendations to FDA on regulatory issues. The committee will discuss considerations related to the use of pertussis controlled human infection models (CHIMs) in pivotal studies to demonstrate efficacy of pertussis vaccines for the purpose of licensure and will hear an overview of the Laboratory of Mucosal Pathogens and Cellular Immunology (LMPCI) research program in the Center for Biologics Evaluation and Research (CBER). At least one portion of the meeting will be closed to the public. FDA is establishing a docket for public comment on this document.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting, the background material will be made publicly available on FDA's website at the time of the advisory committee meeting. Background material and the link to the online teleconference and/or video conference meeting will be available at: https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee meeting link. The meeting will include slide presentations with audio and video components to allow the presentation of materials in a manner that most closely resembles an in-person advisory committee meeting.

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (<u>CVEP</u>) / GE2P2 Global Foundation, which is solely responsible for its content.

:::::::

Copyright GE2P2 Global Foundation 2024. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

:::::::

CVEP is a program of the <u>GE2P2 Global Foundation</u> whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable

development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the <u>Bill & Melinda Gates Foundation</u>; the <u>Bill & Melinda Gates Medical Research Institute</u>, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.